SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report:
February 26, 1999
BENTLEY PHARMACEUTICALS, INC.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Florida 1-10581 59-1513162
--------------------------- ---------- ---------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
Two Urban Centre, Suite 400, 4890 West Kennedy Blvd., Tampa, FL 33609
- ---------------------------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
(813) 281- 0961
--------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
<PAGE>
Item 2. Acquisition and Disposition of Assets.
- ------ -------------------------------------
On February 11, 1999, Bentley Pharmaceuticals, Inc.
(the "Registrant") acquired rights to certain U.S. and
international patents and related technology (the "Assets")
covering methods to enhance the absorption of drugs delivered
to biological tissues, effective as of December 31, 1998.
Consideration for the Assets was paid to Yungtai Hsu, an
individual, in the form of a cash payment of approximately
$1.1 million, 225,800 shares of common stock and ten year
warrants to purchase 450,000 shares of common stock. In
addition, 359,282 shares of common stock were conveyed to
Conrex Pharmaceutical Corporation, for total consideration of
approximately $2.25 million for the Assets. Furthermore, terms
of this transaction provide for certain royalty payments upon
commercialization of products using the technologies.
The Registrant used a portion of the proceeds of the
exercise of its publicly held Class A warrants to pay the cash
portion of the purchase price. The consideration for the
Assets was determined by arms-length negotiation between the
parties. There are no material relationships between Yungtai
Hsu or Conrex and the Registrant or any of its affiliates, its
directors, its officers or any associate of any such directors
or officers.
Item 7. Financial Information and Exhibits.
- ------ ----------------------------------
(c) Exhibits:
Exhibit Number Description
7.1 Agreement between the Registrant and Yungtai Hsu
("Hsu"), dated February 1, 1999, effective as of December
31, 1998.
7.2 Subscription Agreement between the
Registrant and Hsu, dated February 11, 1999.
7.3 Registration Rights Agreement between the Registrant and
Hsu, dated February 11, 1999.
7.4 Warrant issued by the Registrant for the benefit
of Hsu, dated February 11, 1999
-2-
<PAGE>
7.5 Subscription Agreement between the Registrant and Conrex
Pharmaceutical Corporation ("Conrex"), dated February 11,
1999.
7.6 Registration Rights Agreement between the
Registrant and Conrex, dated February 11, 1999.
-3-
<PAGE>
S I G N A T U R E
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BENTLEY PHARMACEUTICALS, INC.
(Registrant)
Date: February 26, 1999 By: /s/ Michael D. Price
---------------------------------------
Michael D. Price
Vice President & Chief Financial Officer
-4-
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Number Description
7.1 Agreement between the Registrant and Yungtai Hsu
("Hsu") dated February 1, 1999, effective as of
December 31, 1998.
7.2 Subscription Agreement between the Registrant and
Hsu, dated February 11, 1999.
7.3 Registration Rights Agreement between the Registrant
and Hsu, dated February 11, 1999.
7.4 Warrant issued by the Registrant for the benefit of
Hsu, dated February 11, 1999.
7.5 Subscription Agreement between the Registrant and
Conrex Pharmaceutical Corporation ("Conrex"), dated
February 11, 1999.
7.6 Registration Rights Agreement between the Registrant
and Conrex, dated February 11, 1999.
-5-
Asset Purchase Agreement
between
BENTLEY PHARMACEUTICALS, INC.
and
YUNGTAI HSU
DATED FEBRUARY 1, 1999 EFFECTIVE AS OF DECEMBER 31, 1998
<PAGE>
TABLE OF CONTENTS
Page
ARTICLE I DEFINITIONS...............................................1
1.01 Definitions. ............................................1
ARTICLE II SALE OF ASSETS AND CLOSING................................5
2.01 Purchase And Sale of Assets...............................5
2.02 Assumption of Obligations And Liabilities.................5
2.03 Retained Liabilities......................................6
2.04 Purchase Price; Allocation; Adjustment....................6
2.05 Closing...................................................7
2.06 Third-Party Consents......................................8
2.07 Assignment................................................8
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER..................9
3.01 Intentionally Omitted.....................................9
3.02 Legal Capacity............................................9
3.03 Execution and Binding Effect..............................9
3.04 Title.....................................................9
3.05 Registrations.............................................9
3.06 Intellectual Property....................................10
3.07 Absence of Certain Changes or Events.....................10
3.08 Contracts................................................11
3.09 Negotiations.............................................12
3.10 Litigation...............................................12
3.11 Compliance with Law......................................12
3.12 Licenses and Regulatory Reports..........................13
3.13 Inspections and Agreements with Governmental or
Regulatory Authorities.................................13
3.14 Affiliate Interests......................................13
3.15 Absence of Undisclosed Liabilities.......................14
3.16 Customers, Licensees and Suppliers.......................14
3.17 Commitments..............................................14
3.18 Other Contracts..........................................14
3.19 Brokers and Finders......................................14
3.20 Tax Matters..............................................15
3.21 Disclosure...............................................15
3.22 Purchase of Assets.......................................16
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER..............16
4.01 Organization and Good Standing...........................16
4.02 Authority................................................16
-ii-
<PAGE>
TABLE OF CONTENTS (cont'd)
Page
4.03 Execution and Binding Effect.............................17
4.04 Brokers and Finders......................................17
4.05 Disclosure...............................................17
ARTICLE V COVENANTS OF SELLER......................................17
5.01 Regulatory and Other Approvals...........................17
5.02 No Solicitations.........................................18
5.03 Conduct relating to the Assets...........................18
5.04 Licenses; Filings........................................19
5.05 Certain Restrictions.....................................19
5.06 Delivery of Business Information.........................20
5.07 Non-competition..........................................20
5.08 Notice and Cure..........................................21
5.09 Fulfillment of Conditions................................21
ARTICLE VI COVENANTS OF PURCHASER...................................21
6.01 Regulatory and Other Approvals...........................21
6.02 Notice and Cure..........................................22
6.03 Delivery of Documents....................................22
6.04 Fulfillment of Conditions................................22
ARTICLE VII CONDITIONS TO OBLIGATIONS OF SELLER......................22
7.01 Representations, Warranties and Covenants................23
7.02 Performance..............................................23
7.03 Laws.....................................................23
7.04 Officer's Certificate....................................23
7.05 Regulatory Consents and Approvals........................23
7.06 Opinion of Counsel.......................................23
7.07 Delivery of Documents....................................23
7.08 Proceedings..............................................23
ARTICLEV III CONDITIONS TO OBLIGATIONS OF PURCHASER...................24
8.01 Representations, Warranties and Covenants................24
8.02 Performance..............................................24
8.03 Laws.....................................................24
8.04 Regulatory Consents and Approvals........................24
8.05 Third Party Consents.....................................24
8.06 Delivery of Assets and Documents.........................25
8.07 Opinion of Counsel.......................................25
8.08 Tax Status...............................................25
-iii-
<PAGE>
TABLE OF CONTENTS (cont'd)
Page
8.09 Proceedings..............................................25
ARTICLE IX ADDITIONAL POST-CLOSING COVENANTS........................25
9.01 Further Assurances, Post-Closing Cooperation.............25
9.02 FDA Approvals............................................27
9.03 Adverse Drug Experience; Recalls.........................27
9.04 Delivery of Shares.......................................27
9.05 Non-Assertion of Patent..................................27
ARTICLE X INDEMNIFICATION..........................................27
10.01 Survival of Representations, Warranties, Covenants
and Agreements........................................27
10.02 Purchaser's Indemnified Liabilities......................28
10.03 Seller's Indemnified Liabilities.........................28
10.04 Notice and Defense of a Claim............................28
ARTICLE XI TERMINATION..............................................29
11.01 Termination..............................................29
11.02 Effect of Termination....................................30
ARTICLE XII MISCELLANEOUS............................................30
12.01 Notices..................................................30
12.02 Amendments...............................................31
12.03 Binding Effect; Assignment...............................31
12.04 Announcements............................................32
12.05 Expenses.................................................32
12.06 Entire Agreement.........................................32
12.07 Descriptive Headings.....................................32
12.08 Counterparts.............................................32
12.09 Governing Law; Jurisdiction..............................32
12.10 Arbitration of Disputes..................................32
12.11 Severability.............................................33
12.12 Confidentiality..........................................34
-iv-
<PAGE>
EXHIBITS
Exhibit A Disclosure Schedule
Exhibit B Subscription Agreement
Exhibit C Registration Rights Agreement
Exhibit D Warrant Agreement
Exhibit E Assumption Agreement
Exhibit F General Assignment and Bill of Sale
Exhibit G Form of Assignment of Intellectual Property
Exhibit H Form of Opinion of Counsel of Purchaser
Exhibit I Form of Opinion of Counsel of Seller
Exhibit J Power of Attorney
Exhibit K Letter to Drug Master File Staff
INDEX TO EXHIBITS - DISCLOSURE SCHEDULE
Schedule 1.01(b) Contracts
Schedule 1.01(c) Suppliers and Supply Agreements
Schedule 1.01(g) Licenses
Schedule 1.01(h) Patents
Schedule 2.04(a) Collaborative Parties
Schedule 2.04(c) Allocation of Purchase Price
Schedule 3.03 Seller's Required Filings
Schedule 3.05 Registrations
Schedule 3.06 License Agreements
Schedule 3.07 Changes or Events
Schedule 3.10 Litigation
Schedule 3.16(a) Suppliers
Schedule 3.16(b) Customers and Licensees
Schedule 3.19 Seller's Brokers and Finders
Schedule 4.03 Purchaser's Required Filings
-v-
<PAGE>
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT (the "Agreement") is dated
February 1, 1999 made and entered into effective as of December 31, 1998 between
YUNGTAI HSU, in his personal capacity ("Seller") and BENTLEY PHARMACEUTICAL,
INC., a Florida corporation ("Purchaser").
WHEREAS, Seller purchased the Assets (as defined below) from
Conrex Pharmaceutical Corporation, a New Jersey corporation ("Conrex");
WHEREAS, simultaneously herewith the Seller and Purchaser have
entered into a voting agreement relating to the purchase of the Assets from
Conrex;
WHEREAS, Purchaser desires to purchase from Seller, and Seller
desires to sell to Purchaser the Assets (as defined below) which Seller
purchased from Conrex, all on the terms and subject to the conditions set forth
herein; and
NOW, THEREFORE, in consideration of the premises and of the
mutual agreements herein contained, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:
ARTICLE I
DEFINITIONS
1.01 Definitions. As used in this Agreement, the following defined
terms have the meanings indicated below:
"Action or Proceeding" means any action, claim, suit, proceeding,
inquiry, arbitration or Governmental or Regulatory Authority investigation or
audit.
"Affiliate" means any Person that directly, or indirectly through one
of more intermediaries, controls or is controlled by or is under common control
with the Person specified. For purposes of this definition, control of a Person
means the power, direct or indirect, to direct or cause the direction of the
management and policies of such Person whether by Contract or otherwise and, in
any event and without limitation of the previous sentence, any Person owning ten
percent or more of the voting securities of another Person shall be deemed to
control that Person.
"Assets" means:
(a) the Technology;
<PAGE>
(b) the Business Information;
(c) the Patents;
(d) all Contracts relating to the Patents and Technology that
are listed or described on Schedule 1.01(b) of the Disclosure Schedule,
including without limitation, Seller's rights to receive goods and services, to
assert claims and to take other action with respect to breaches, defaults and
other violations pursuant to all of the Contracts;
(e) all Licenses;
(f) lists of suppliers and supply agreements, if any, listed
on Schedule 1.01(c) of the Disclosure Schedule; and
(g) all batch records in existence as of the date hereof and
as of the Closing Date.
"Assigned Contracts" means the Contracts to be assigned by Seller to
Purchaser as set forth on Schedule 1.01(b) of the Disclosure Schedule.
"Assigned Licenses" means the Licenses to be assigned by Seller to
Purchaser as set forth on Schedule 1.01(g) of the Disclosure Schedule.
"Associate" means, with respect to any Person, any corporation or other
business organization of which such Person is an officer or partner or is the
beneficial owner, directly or indirectly, of ten percent or more of any class of
equity securities, any trust or estate in which such Person has a substantial
beneficial interest or as to which such Person serves as a trustee or in a
similar capacity and any relative or spouse of such Person, or any relative of
such spouse, who has the same home as such Person.
"Assumed Liabilities" has the meaning ascribed to it in Section 2.02.
"Business Day" means a day other than Saturday, Sunday or any day on
which banks located in the State of New York are authorized or obligated to
close.
"Business Information" means lists of, and all records, in written,
electronic, or other formats, and other data, regarding:
(a) pharmaceutical research relating to the Patents and
Technology,
(b) suppliers, strategies, formulae, training manuals and
customers relating to the development of the Patents and Technology, performance
statistics and all other correspondence, records, reports, computer disks and
programs (including source codes), tapes and other files,
-2-
<PAGE>
information and records, including, but not limited to, all regulatory files,
records and other correspondence, including the DMF and all original
(laboratory) notebooks in a complete and unabridged or altered form, and the
records, reports and data relating thereto;
(c) Seller's files relating to potential applications of the
Patents and Technology,
(d) interest expressed by any Person in collaborating with
Seller for researching, developing, licensing, manufacturing or marketing the
Patents and/or the Technology for pharmaceutical industry applications (as
defined by its intended indication);
(e) Seller's ownership and operation of the Assets; and
(f) the Intellectual Property.
"Closing" means the closing of the transactions contemplated by Section
2.01.
"Closing Date" means February 11, 1999, effective as of December 31,
1998, or such other date as Purchaser and Seller mutually agree upon in writing.
"Contract" means any agreement, understanding, lease, license, evidence
of indebtedness, mortgage, indenture, security agreement or other contract,
whether written or oral.
"Disclosure Schedule" means the record delivered to Purchaser by Seller
and initialed by Seller and Purchaser, dated as of the date hereof and attached
hereto as Exhibit A, containing all schedules as are required to be included
pursuant to this Agreement.
"DMF" means the Drug Master file as compiled by Seller;
"Governmental or Regulatory Authority" means any court, tribunal,
arbitrator, authority, agency, commission, official or other instrumentality of
the United States, any foreign country or any domestic or foreign state, county,
city, municipality or other political subdivision.
"Indemnified Party" has the meaning ascribed to it in Section 10.04.
"Indemnifying Party" has the meaning ascribed to it in Section 10.04.
"Intellectual Property" means the Patents and all trade computer
programs (including all source codes) and related documentation, technical
information, analytical methods, manufacturing, engineering and technical
drawings and know-how relating to the Technology.
"Laws" means all laws, statutes, rules, regulations, ordinances,
permits, orders, writs, judgments, awards, injunctions or decrees or other
pronouncements having the effect of law of the
-3-
<PAGE>
United States, any foreign country or any domestic or foreign state, county,
city or other political subdivision or of any Governmental or Regulatory
Authority.
"Licenses" means all licenses, permits, certificates of authority,
authorizations, approvals, registrations, franchises, concessions, grants, and
similar consents granted or issued by any Governmental or Regulatory Authority
required in connection with researching, developing, licensing, manufacturing
and marketing the Technology and Patents, including those Licenses that are
currently being negotiated; and including without limitation, those listed on
Schedule 1.01(g) of the Disclosure Schedule.
"Liens" means any mortgage, pledge, assessment, security interest,
lease, lien, adverse claim, levy, charge, restriction or other encumbrance or
restriction of any kind, or any conditional sale Contract, title retention
Contract or other Contract to give any of the foregoing.
"Loss" means any and all damages, fines, fees, penalties, deficiencies,
losses and expenses (including, without limitation, interest, court costs, fees
of attorneys, accountants and other experts or other expenses of litigation or
other proceedings or of any claim, default or assessment).
"Order" means any writ, judgment, decree, injunction or similar order
of any Governmental or Regulatory Authority, in each such case whether
preliminary or final.
"Patents" means (i) United States Patent No. 5,023,252 (the "U.S.
Patent") and any reissue thereof, any reexamination thereof, and any extension
thereof and any patent application or patent in any other country which
discloses and claims subject matter which is disclosed in the U.S. Patent,
including the patents which are listed in Schedule 1.01(h) of the Disclosure
Schedule, and (ii) any patent application which is hereafter filed and which is
entitled to the benefit of the filing date of U.S. Application No. 08/954,869
(the "869 Application"), filed October 21, 1997, and which claims pharmaceutical
subject matter that is disclosed in the 869 Application and any patent which may
issue thereon and any reissue thereof, any reexamination thereof, and any
extension thereof. "Patents" does not mean U.S. patent No. 5,731,303 (hereafter
the "303 Patent") or any patent or patent application which discloses and claims
subject matter which relates to a composition that contains a cosmetic
skin-treating compound or a cosmetic hair-treating compound, as described in the
303 Patent, or to the use of such cosmetic composition.
"Person" means any natural person, corporation, general partnership,
limited partnership, proprietorship, other business organization, trust, union,
association or Governmental or Regulatory Authority.
"Purchase Price" has the meaning ascribed to it in Section 2.04.
"Purchaser's Indemnified Liabilities" has the meaning ascribed to it in
Section 10.02.
"Purchaser" means Bentley Pharmaceuticals, Inc., a Florida corporation.
-4-
<PAGE>
"Seller" means Yungtai Hsu, in his personal capacity, or any lawful
successor in interest to Yungtai Hsu.
"Seller Documents" means the arrangements, documents, instruments and
certificates required to be executed and delivered by Seller in connection with
this Agreement.
"Seller's Indemnified Liabilities" has the meaning ascribed to it in
Section 10.03.
"Taxes" means all Tax Returns of or relating to any foreign, federal,
state or local tax, assessment, levy, impost, duty, withholding or other similar
governmental charge, all, together with any penalties, additions to tax, fines,
interest and similar charges thereon or related thereto.
"Tax Returns" means all returns, including, without limitation, income,
franchise, sales and use, unemployment compensation, excise, severance,
property, gross receipts, profits, payroll and withholding tax returns and
information returns, and reports.
"Technology" means any and all information relating to a composition
containing a drug and a compound (hereafter "Enhancer") which increase the rate
of passage of the drug across the skin or other body membrane, for example,
mucous membranes, or the blood brain barrier and to the administration of such
composition to treat humans (hereafter "pharmaceutical subject matter"), such
information including information related to all developmental and commercially
practiced processes and methodologies (including, but not limited to, methods of
using, storing, identifying, measuring, and analyzing the composition),
formulations, trade secrets, know how, formulae and manufacturing, processing
and other technical information and underlying data as it applies to
pharmaceutical industry application (as defined by the FDA), prescription and
over-the-counter application. "Technology" does not mean information which
relates to a cosmetic composition which contains a cosmetic skin-treating
compound or a cosmetic hair-treating compound and an Enhancer or to the use of
such cosmetic composition.
ARTICLE II
SALE OF ASSETS AND CLOSING
2.01 Purchase And Sale of Assets. On the terms and subject to the
conditions set forth in this Agreement, at the Closing Purchaser shall purchase
from Seller, and Seller shall sell, transfer, assign, convey and deliver to
Purchaser all of Seller's right, title and interest in and to the Assets, free
and clear of any and all Liens. As a result of this transaction, Seller shall
retain no interest whatsoever in the Assets.
2.02 Assumption of Obligations And Liabilities. On the terms and
subject to the conditions set forth in this Agreement, from and after the
Closing, Purchaser will assume and pay, perform, discharge and be responsible
only for those obligations and liabilities of Seller under the Assigned
-5-
<PAGE>
Contracts and Assigned Licenses which accrue after the Closing Date (the
"Assumed Liabilities"); provided that Purchaser shall have the right, in its
sole discretion, and without effect on the Purchase Price, to add or delete
Assigned Contracts or Assigned Licenses by written notice delivered to Seller
two Business Days prior to the Closing Date, or such earlier date as Seller's
right to add or delete such Assigned Contracts or Assigned Licenses by written
notice delivered to Conrex terminates.
2.03 Retained Liabilities. Notwithstanding anything herein or in the
Seller Documents to the contrary, Purchaser shall not assume or pay, perform,
discharge or be responsible for any of the obligations or liabilities of Seller,
including but not limited to Seller's liabilities to Virna Pharmaceuticals, Inc.
or with respect to and arising out of an agreement between Seller and Virna
Pharmaceuticals, Inc., effective as of December 1, 1990, as further amended (the
"Retained Liabilities") other than the Assumed Liabilities. Seller shall
discharge in a timely manner or shall make adequate provision for the Retained
Liabilities. Purchaser is not a successor to Seller for any purpose and shall
not be liable for any claim that may exist against Seller, including but not
limited to any products liability claims.
2.04 Purchase Price; Allocation; Adjustment.
(a) Purchase Price. The aggregate purchase price for the
Assets and for the covenant of Seller contained in Section 5.07 shall be (i)
U.S. $1,074,000 (the "Cash Portion of the Purchase Price"), subject to the
adjustments as provided in paragraph (b) below; (ii) an aggregate of $350,000 of
shares of common stock (the "Shares") of Purchaser according to the terms and
conditions of the Subscription Agreement and the Registration Rights Agreement,
dated as of the Closing Date, substantially in the forms of Exhibit B and C,
respectively, hereto, (iii) a warrant to purchase 450,000 shares of common stock
of Purchaser according to the terms and conditions of the Warrant Agreement,
dated as of the Closing Date, substantially in the form of Exhibit D hereto,
(iv) 5% of the net profits received by Purchaser or its successors for fifteen
years from the Closing Date from the commercialization of any products developed
by Purchaser or its successors from the Assets and (v) the aggregate amount of
the Assumed Liabilities ((i)-(v) collectively, the "Purchase Price").
(b) Adjustment of Cash Portion of Purchase Price. The Cash
Portion of the Purchase Price shall be adjusted downward to an amount of
$1,024,000 (the "Adjusted Cash Portion of the Purchase Price") to reflect a
payment by Purchaser to Seller on December 3, 1998 of a $50,000 due-diligence
deposit.
(c) Allocation of Purchase Price. Purchaser and Seller hereby
agree that for tax purposes the Purchase Price will be allocated in accordance
with Schedule 2.04(c) of the Disclosure Schedule, which allocation shall be
binding upon the Purchaser and the Seller, each of which agrees to report the
effect of the transactions contemplated hereby on all applicable Tax Returns or
filings in a manner consistent with such schedule. The Seller hereby assumes
liability for and shall pay all sales, transfer and similar Taxes incurred as a
result of the sale of the Assets to Purchaser.
-6-
<PAGE>
2.05 Closing.
(a) The Closing will take place at the offices of Synnestvedt
& Lechner LLP, 2600 Aramak Tower, 1101 Market Street, Philadelphia, Pennsylvania
19107, or at such other place as Purchaser and Seller mutually agree, at 10:00
A.M. Eastern Standard Time, on the Closing Date.
(b) Deliveries by Purchaser to Seller. At the Closing,
Purchaser will:
(i) deliver to Seller an executed copy of this
Agreement;
(ii) pay the Adjusted Cash Portion of the Purchase
Price by wire transfer of immediately available funds to such
account as Seller may reasonably direct by written notice
delivered to Purchaser by Seller at least two Business Days
before the Closing Date;
(iii) deliver to Seller the Subscription Agreement,
Registration Rights Agreement and Warrant Agreement, duly
executed by Purchaser;
(iv) deliver to Seller an assumption agreement, dated
as of the Closing Date, substantially in the form of Exhibit E
hereto, duly executed by Purchaser, pursuant to which
Purchaser assumes all of the Assumed Liabilities;
(v) deliver to Seller the certificate referred to in
Section 7.04; and
(vi) deliver to Seller the opinion referred to in
Section 7.06.
(c) Deliveries by Seller to Purchaser. Simultaneously with the
deliveries by Purchaser, Seller will:
(i) deliver to Seller an executed copy of this
Agreement;
(ii) assign and transfer to Purchaser good and valid
title in and to the Assets (free and clear of all Liens) by
delivery of (A) a General Assignment and Bill of Sale
substantially in the form of Exhibit F hereto, duly executed
by Seller, (B) an assignment of the Intellectual Property in
form and substance reasonably satisfactory to Purchaser to
vest in Purchaser all of Seller's right, title and interest
in, to and under the Patents , including but not limited to
instruments of assignment in a form suitable for filing with
the U.S. Patent and Trademark Office (including, but not
limited to, United States Patent and Trademark Office Form No.
SB/41) to reflect the transfer of the Patents included in the
Assets and, upon filing such instrument with the U.S. Patent
and Trademark Office, to record the sale of all of Seller's
right, title and interest in, to and under the Patents to the
Purchaser, and (C) such other good and
-7-
<PAGE>
sufficient instruments of conveyance, assignment and transfer,
in form and substance reasonably acceptable to Purchaser's
counsel, as shall be effective to vest in Purchaser good and
marketable title to the Assets, free of all Liens, including,
but not limited to, written notices from Seller to all parties
under any Contract relating to the Assets, addressed to such
parties, in the form prepared by Seller and reasonably
acceptable to Purchaser, for the release of such Contracts;
(iii) deliver to Purchaser a receipt for the Purchase
Price;
(iv) deliver to Purchaser regulatory consents and
approvals and third-party consents referred to in Sections
8.04 and 8.05;
(v) deliver to Purchaser the opinion referred to in
Section 8.07;
(vi) make available to Purchaser, at the location of
the Assets, all Assets; and
(vii) Seller shall deliver to Purchaser, such further
instruments of transfer as Purchaser shall reasonably request,
to vest in Purchaser all of Sellers' right, title and interest
in and to the Assets, including, but not limited to, any
documents evidencing the assignment to Purchaser of the
Intellectual Property (which documents are attached hereto as
Exhibit G), and take such other actions as Purchaser shall
reasonably request to enable Purchaser to use such Assets, as
contemplated herein and in the Seller Documents.
2.06 Third-Party Consents. To the extent that any Contract or License
is not assignable without the consent of another party, this Agreement shall not
constitute an assignment or an attempted assignment thereof if such assignment
or attempted assignment would constitute a breach thereof. Seller and Purchaser
shall use their best efforts to obtain the consent of such other party to the
assignment of any such Contract or License to Purchaser in all cases in which
such consent is or may be required for such assignment. If any such consent
shall not be obtained, Seller shall cooperate with Purchaser in any reasonable
arrangement designed to provide for Purchaser the benefits intended to be
assigned to Purchaser under the relevant Contract or License, including
enforcement at the cost and for the account of Seller of any and all rights of
Seller against the other party thereto arising out of the breach or cancellation
thereof by such other party or otherwise. If and to the extent that such
arrangement cannot be made, Purchaser shall have no obligation pursuant to
Section 2.02 or otherwise with respect to any such Contract or License. The
provisions of this Section 2.06 shall not affect the right of Purchaser not to
consummate the transactions contemplated by this Agreement if the condition to
its obligations hereunder contained in Section 8.05 has not been fulfilled.
2.07 Assignment. Seller hereby assigns to Purchaser all of his rights
under that certain Asset Purchase Agreement dated February 1, 1999 effective as
of December 31, 1998 between Conrex and Seller (the "Conrex Agreement").
-8-
<PAGE>
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller understands that each of the following representations and
warranties are material and have been relied on by Purchaser. Seller represents,
warrants and covenants to Purchaser that the statements contained in this
Article III are correct and complete as of the date of this Agreement, and will
be correct and complete as of the Closing Date (as though made on the Closing
Date), except as set forth in the Disclosure Schedule delivered to Purchaser on
the date of this Agreement and initialed by Seller and Purchaser.
3.01 Intentionally Omitted.
3.02 Legal Capacity. Seller has full power and legal capacity to
execute, deliver and perform this Agreement and the Seller Documents to which he
is a party and to consummate the transactions contemplated hereby and thereby.
3.03 Execution and Binding Effect. This Agreement has been, and each of
the Seller Documents will be, at or prior to the Closing, duly executed and
delivered by Seller and this Agreement constitutes, and the Seller Documents
when so executed and delivered, will constitute legal, valid and binding
obligations of Seller, enforceable against Seller in accordance with their
respective terms except as such enforceability may be limited by bankruptcy,
insolvency or similar laws and by equitable principles. None of the execution
and delivery by Seller of this Agreement and the Seller Documents, or the
consummation of the transactions contemplated hereby or thereby, or compliance
by Seller with any of the provisions hereof or thereof will (a) conflict with,
violate, result in the breach or termination of, or constitute a default under
(i) any Laws or (ii) any requirement of any Governmental or Regulatory Authority
applicable to Seller or by which the Assets may be bound, or (c) except as set
forth on Schedule 3.03 of the Disclosure Schedule, require any filing,
declaration or registration with, or permit, consent, approval, waiver,
clearance, order or authorization of, or the giving of any notice to, any
Governmental or Regulatory Authority or other Person or (d) result in the
creation of any Lien (other than any lien in favor of Purchaser) upon any of the
Assets.
3.04 Title. Seller has good and marketable title to all of the Assets
and will convey good and marketable title at the Closing, free and clear of any
and all Liens. None of the Assets is licensed or otherwise not owned by Seller.
In transferring the Assets to Purchaser, Seller has no intent to hinder, delay
or defraud any entity to which Seller owes or will owe any debt, on or after the
Closing Date.
3.05 Registrations. The registrations listed on Schedule 3.05 of the
Disclosure Schedule are the only registrations, as of the Closing Date, required
by any Governmental or Regulatory Authority to develop, manufacture, market and
sell the Technology and Patents and any products resulting from the Technology
and the Patents. Such Registrations are and will be valid, current and held
exclusively by Seller as of the Closing Date.
-9-
<PAGE>
3.06 Intellectual Property. The Intellectual Property constitutes all
intellectual property which is necessary or used by Seller, to develop,
manufacture, market and sell products developed from the Patents or the
Technology. All of the Intellectual Property that is owned by Seller is owned
free and clear of all Liens and all Intellectual Property that is licensed or
otherwise used by Seller is licensed pursuant to valid and existing license
agreements and such interests are not subject to any Liens other than the
applicable license agreement, if any. All such license agreements are set forth
on Schedule 3.06 of the Disclosure Schedule. Seller has not granted to any
Person any License, interest or other right in respect of the Intellectual
Property which does, or which will, as of the Closing or subsequent to the
Closing, permit any other Person, other than Purchaser, to use any of the
Intellectual Property. All Intellectual Property, including without limitation,
the Patents, is valid, effective and enforceable. Seller is unaware of any
reason that the Intellectual Property, is or could be, invalid or unenforceable,
including, but not limited to, the failure of Seller to timely pay any fees or
dues associated with the Intellectual Property. To the best knowledge of Seller,
no Actions or Proceedings are pending or threatened, questioning the validity or
effectiveness of any Intellectual Property or asserting that Seller is
infringing or otherwise adversely affecting the rights of any Person with regard
to any intellectual property of such Person. The Intellectual Property is not
being infringed by any Person and Seller, to the best of his knowledge, is
unaware of any potential infringement of the Intellectual Property. No third
party intellectual property will be infringed as a result of the use of the
Assets. There are no royalties, fees or other amounts payable by or to Seller
with respect to any of the Intellectual Property. The consummation of the
transactions contemplated by this Agreement and the Seller Documents will not
result in the loss of any Intellectual Property or rights therein.
3.07 Absence of Certain Changes or Events.
(a) Except as set forth in Schedule 3.07 of the Disclosure
Schedule, Seller has used the Assets only in the ordinary and usual course of
his business consistent with past practice, and has not:
(i) placed Liens or allowed Liens to be placed on the
Assets;
(ii) canceled or compromised any material claims, or
waived any other material rights, or sold, transferred or
otherwise disposed of any of the Assets;
(iii) sold, transferred, licensed, assigned or
otherwise disposed of, or permitted to lapse or disclosed to
any Person (other than disclosure to his employees or agents,
as reasonably necessary in the ordinary and usual course of
his business), any of the Intellectual Property or Business
Information;
(iv) suffered any material adverse change in the
manufacturing and development of the Patents or Technology; or
-10-
<PAGE>
(v) agreed in writing or otherwise to take any action
described in this Section 3.07.
(b) Except as set forth in Schedule 3.07 of the Disclosure
Schedule, Seller is not aware of any event, fact or condition that has occurred
or could reasonably be expected to occur that has or has resulted in, or is
reasonably likely to result, in a material adverse change in research,
development, licensing, manufacture, marketing or sale of the Assets.
3.08 Contracts.
(a) Except as set forth in Schedule 1.01(b) of the Disclosure
Schedule, none of the Assets is subject to, and except as set forth in Schedule
1.01(b) of the Disclosure Schedule, Seller is not a party to or bound by:
(i) any Contract relating to the Assets;
(ii) any Contract limiting the freedom of Purchaser
or any affiliate thereof following the Closing to engage in
any line of business, to own, operate, sell, transfer, pledge
or otherwise dispose of or encumber the Assets or to compete
with any Person or to engage in any business or activity in
any geographic area, within the United States or outside of
the United States, relating to the Assets;
(iii) any Contract with any partnership, joint
venture or other entity;
(iv) any sale, loan, charge, Contract or other
transaction between Seller and any of his shareholders,
affiliates, directors or officers; or
(v) any Contract that is or might otherwise
reasonably be expected to be material to the Assets (for
purposes of this clause (v), a Contract involving payments to
or by Seller shall be deemed to be material if such payments
are in an aggregate amount of $1,000 or more).
(b) Seller is not in breach of any provision of, or in default
(and knows of no event or circumstance that with notice, or lapse of time or
both, would constitute an event of default) under the terms of any Contract
described in Schedule 1.01(b) of the Disclosure Schedule nor is there any Action
or Proceeding or grievance alleging such a breach or default. Seller is not
aware, or could not be reasonably aware, of any breach by any other party to any
Contract described in Schedule 1.01(b) of the Disclosure Schedule. All Contracts
described in Schedule 1.01(b) of the Disclosure Schedule are in full force and
effect, will continue to be in full force and effect after the Closing and
Seller is not aware, or could not be reasonably aware, of any pending or
threatened disputes with respect to such Contracts. Seller is not engaged in any
disputes with customers or suppliers, and to Seller's knowledge (i) no customer
or supplier is considering termination, non-renewal or any adverse
-11-
<PAGE>
modification of its arrangements with Seller, and (ii) the transactions
contemplated by this Agreement will not have an adverse affect on the business
relationship with any of its suppliers or customers.
(c) All of the Contracts (i) have been entered into on an
arm's-length basis, (ii) are within the scope of their corporate purpose and
ordinary business, (iii) do not violate applicable Laws, (iv) are not of a
loss-making nature, that is known to be likely to result in a loss on completion
or performance and (v) contain termination provisions which are reasonable and
customary for the type of transactions and activities to which they relate.
Seller has not entered into any Contract which cannot be readily fulfilled or
performed on time without undue or unusual expenditure of money or effort.
3.09 Negotiations. Schedule 2.04 (a) of the Disclosure Schedule sets
forth, in a complete and exhaustive manner, any and all negotiations and
discussions between Seller and any other Person relating to any of the Assets.
Schedule 2.04(a) of the Disclosure Schedule sets forth details regarding the
status of negotiations for each party listed on such schedule.
3.10 Litigation. Except as set forth on Schedule 3.10 of the Disclosure
Schedule, there is not currently, and there has not been at any time, any
Actions or Proceedings pending or threatened by or against Seller or any
affiliate or employee of Seller, or with respect to the Assets (including,
without limitation, products liability claims) or the transactions contemplated
hereby, at law or in equity or before or by any Governmental Entity or
arbitrator, which has had or could have a material adverse affect on Purchaser
or the Assets, and, to the best knowledge of Seller, there is no valid basis for
any such Action or Proceeding. Except as set forth on Schedule 3.10 of the
Disclosure Schedule, there is no pending or threatened Action or Proceeding that
seeks to enjoin or obtain damages in respect of the consummation of the
transactions contemplated by this Agreement or that questions the validity of
this Agreement, any of the Seller Documents or any action to be taken by Seller
in connection with the consummation of the transactions contemplated hereby or
thereby. Seller is not subject to any Laws or, to the best of Seller's
knowledge, any proposed Laws, which has had or could have a material adverse
affect on the Assets or on Purchaser's ability to manufacture any products from
the Patents or Technology.
3.11 Compliance with Law. Seller has operated and is currently
conducting all research, development, manufacture, and sales relating to the
Assets, and all products resulting from the Patents or Technology have been
provided, developed, marketed and sold in compliance with all applicable Laws of
Governmental or Regulatory Authority. Seller has not received notice of, and
does not have knowledge of any such violation or alleged violation with respect
to the Assets. Seller has not received notice of (and does not have knowledge
of) (a) any finding of any lack of efficacy with respect to any products
resulting from the Assets or (b) any findings, determinations, studies, reports,
analyses, investigations, inquiries or Legal Proceedings by or for any
Governmental or Regulatory Authority with respect to the efficacy of any
products resulting from the Assets. As of the date hereof and as of the Closing
Date, all reports relating to the Assets required to be filed by Seller with any
Governmental or Regulatory Authority have been or will have been filed and are
and will be accurate and complete in all material respects when filed.
-12-
<PAGE>
3.12 Licenses and Regulatory Reports.
(a) Seller possesses all Licenses required to be possessed by
it pursuant to all applicable Laws and all such Licenses, as set forth on
Schedule 1.01(g) of the Disclosure Schedule, are in full force and effect. All
Licenses that Seller has been negotiating, or are being negotiated, are set
forth on Schedule 1.01(g) of the Disclosure Schedule and include the name of the
contact person of the potential licensee, the name of the attorney representing
the potential licensee and the status of license being negotiated. Seller is in
compliance with all of his Licenses and there is no reasonable basis for the
revocation or suspension of any thereof. The Licenses constitute all the
Licenses required for Seller's ownership of the Assets and the research,
development, manufacture and marketing of products from the Assets, all of which
are transferable and will be transferred to Purchaser at the Closing, and none
of which will expire within the twelve-month period following the Closing Date.
Seller has furnished to Purchaser copies of all reports of inspections relating
to the Assets by Governmental or Regulatory Authorities;
(b) Seller has paid all fees, dues or assessments, due and
payable in connection with any of the Assets, including, but not limited to,
fees related to the Patents. There is no unresolved violation, criticism or
exception by any entity with respect to any report or statement relating to an
examination of the Assets;
(c) Seller has not prepared for filing, or has not filed with
the FDA or any foreign equivalent, any filings, reports, registrations or
statements (including, but not limited to INDs, NDAs, and ANDAs) pertaining to
the Assets and anything related to Seller's business.
(d) Seller has delivered to Purchaser complete and correct
copies of any and all correspondence between the Company and any Governmental or
Regulatory Authority, including, but not limited to, warning letters, notices of
adverse findings and recall notifications.
3.13 Inspections and Agreements with Governmental or Regulatory
Authorities.
(a) Seller has never received a notice of inspection, nor has
ever been inspected by any Governmental or Regulatory Authority, including, but
not limited to, the FDA, OSHA or the Consumer Product Safety Commission.
(b) Seller is not subject to any cease-and-desist or other
order issued by, or a party to any agreement or memorandum of understanding
with, any Governmental or Regulatory Authority relating to or affecting, or
which may affect the Assets.
3.14 Affiliate Interests. Neither Seller nor any employee, debt-holder
or affiliate of Seller:
-13-
<PAGE>
(a) owns any interest (other than through the ownership of
five percent or less of any class of securities registered under the Securities
Exchange Act of 1934, as amended) in any Person which is a competitor, supplier
or customer of any business relating to the Assets;
(b) owns, in whole or in part, any property, asset or right
used in connection with the research, development, manufacture, marketing and
sales relating to the Assets, or products resulting from the Assets;
(c) has an interest in any Contract pertaining to the Assets;
or
(d) owes any money to, or is owed any money by, the Seller.
3.15 Absence of Undisclosed Liabilities. The Seller has no liabilities
or obligations of any nature, whether absolute, accrued, contingent or
otherwise, which individually or in the aggregate are material to the Assets
except for liabilities for performance obligations arising in the ordinary
course of the business relating to the Assets (and not as a result of a breach
or default by the Seller) under the Contracts listed on Schedule 1.01(b) of the
Disclosure Schedule or Contracts not required to be disclosed on that schedule.
3.16 Customers, Licensees and Suppliers. Schedule 3.16(a) of the
Disclosure Schedule sets forth a list of the suppliers (on the basis of revenues
for goods purchased) for any products relating to the Assets for the year ended
December 31, 1998. Since January 1, 1998, no such supplier has ceased or
materially reduced its sales to the Seller, or has threatened to cease or
materially reduce such sales and the Seller has not been engaged in and is not
engaged in any dispute with any of its suppliers. Schedule 3.16(b) of the
Disclosure Schedule sets forth all customers or licensees that the Seller is
negotiating with, or has ever negotiated with, in connection with any products
relating to the Assets.
3.17 Commitments. Seller is not bound under any Contracts to any
purchase commitments, blanket purchase orders, minimum research and development
expenditure obligations or other minimum expenditure obligations.
3.18 Other Contracts. There are no other Contracts between the Seller
and any other Person, to acquire any of the Assets, and no other Person has any
right or option to acquire any of the Assets.
3.19 Brokers and Finders. Except as set forth on Schedule 3.19 of the
Disclosure Schedule, neither the Seller nor any of his employees or Affiliates
have employed any broker or finder or incurred any liability for any brokerage
fees, commissions or finders' fees in connection with the transactions
contemplated by this Agreement or the Seller Documents. Except as set forth on
Schedule 3.19 of the Disclosure Schedule, no Person is entitled to any fee,
commission or like payment in respect thereof based in any manner on any
agreement, arrangement or understanding made by or on behalf of the Seller.
-14-
<PAGE>
3.20 Tax Matters.
(a) All Tax Returns for any Taxes that are required to be
filed on or before the Closing Date, by or on behalf of or with respect to the
Seller or the Assets have been, or will be, timely filed with the appropriate
foreign, federal, state and local authorities. All Taxes required to be paid by
the Seller on or before the date hereof have been paid in full on or before the
date hereof, and all Taxes required to be paid by the Seller on or before the
Closing Date will be paid on or before such date. Seller additionally warrants
that it shall be solely responsible for the payment of any sales or use taxes
arising from this transaction.
(b) All Tax Returns and the information and data contained
therein have been properly and accurately compiled and completed, fairly present
the information purported to be shown therein, and reflect all liabilities for
Taxes for the periods covered by such Tax Returns. Neither the Internal Revenue
Service nor any other taxing authority is now asserting against the Seller, with
respect to any Tax, any adjustment, deficiency or claim for additional Taxes,
nor are there or have there been any such discussions with or without notice
from any such taxing authorities with respect thereto nor, to the best knowledge
of the Seller, is there any basis therefor. There are no outstanding contracts
or waivers extending the statutory period of limitation applicable to any
assessment or audit or any Tax or Tax Return of the Seller.
(c) No Tax Liens exist on any of the Assets.
(d) No written claim has been made by any taxing authority in
a jurisdiction where the Seller does not file Tax Returns that the Seller is or
may be subject to taxation by that jurisdiction.
(e) The Seller is not a party to any joint venture,
partnership, or other arrangement which is treated as a partnership for federal
income tax purposes.
(f) There is no Contract or consent made under Section 341(f)
of the Internal Revenue Code of 1986, as amended (the "Code"), affecting the
Seller.
(g) The Seller is not a party to any tax sharing Contract,
whether formal or informal.
(h) Seller is not a "Foreign Person" within the meaning of
Section 1445(f)(3) of the Code.
3.21 Disclosure. Seller has disclosed in writing all information which
is necessary for an accurate appraisal of the Assets and to research, develop,
market and manufacture products resulting from the Assets; all information given
by Seller relating to the Assets was, when given accurate, complete and not
misleading. The representations and warranties of Seller contained in this
Agreement do not contain any untrue statement of a material fact or omit to
state any material fact
-15-
<PAGE>
necessary in order to make the statements and information contained in this
Agreement and in the Seller Documents not misleading. The representations and
warranties of Seller contained in this Agreement are subject only to the
exceptions expressly made therein which apply only to the specific
representation or warranty with respect in which they are made; (b) are not
limited or conditioned in any way by the fact that Purchaser, its officers,
employees, advisors, consultants and auditors have known or could have known by
any means or as a result of the due diligence review of Seller and the Assets
pursued or to be pursued by Purchaser, its officers, employees, advisors,
consultants and auditors that any of the representations and warranties made by
Seller are not true, correct, exact, accurate and complete; and (c) the
liability of Seller with respect to Purchaser is not limited in any way by the
fact that Purchaser, its officers, employees, advisors, consultants and auditors
have known or could have known by any means or as a result of the due diligence
review of Seller and the Assets pursued or to be pursued by Purchaser, its
officers, employees, advisors, consultants and auditors, that any of the
representations and warranties made by Seller are not true, correct, exact,
accurate and complete.
3.22 Purchase of Assets. Seller acquired the Assets from Conrex in an
arms-length transaction. Conrex has no rights to reacquire the Assets or
challenge or affect in any way detrimental to Purchaser the validity of its sale
of the Assets to Seller or Seller's sale of the Assets to Purchaser. On the
Closing Date, the Purchaser shall have all of the rights of Seller under the
Conrex Agreement.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER
Purchaser understands that each of the following representations and
warranties are material and have been relied on by Seller. Purchaser represents,
warrants and covenants to Seller that the statements contained in this Article
IV are correct and complete as of the date of this Agreement and will be correct
and complete as of the Closing Date (as though made on the Closing Date).
4.01 Organization and Good Standing. Purchaser is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Florida, and has all requisite power and authority to carry on its business as
it is as of the date hereof being conducted, and to execute, deliver and perform
this Agreement.
4.02 Authority. The execution and delivery to Seller of this Agreement
by Purchaser, the performance by Purchaser of its obligations hereunder and the
consummation by Purchaser of the transactions contemplated hereby have been duly
authorized by the board of directors of Purchaser, and no other corporate act or
proceeding on the part of Purchaser is necessary to approve the execution and
delivery of this Agreement, the performance of Purchaser's obligations
hereunder, or the consummation of the transactions contemplated hereby.
-16-
<PAGE>
4.03 Execution and Binding Effect. This Agreement has been duly
executed and delivered by Purchaser and this Agreement constitutes legal, valid
and binding obligations of Purchaser, enforceable against Purchaser in
accordance with its terms except as such enforceability may be limited by
bankruptcy, insolvency or similar laws and by equitable principles. Neither the
execution and delivery by Purchaser of this Agreement, nor the consummation of
the transactions contemplated hereby, nor the compliance by Purchaser with any
of the provisions hereof will (a) conflict with, or result in the breach of, any
provision of Purchaser's Certificate of Incorporation and Bylaws, as of the
Closing Date, (b) conflict with, violate, result in the breach or termination
of, or constitute a default under (i) any Contract, to which Purchaser is a
party or by which Purchaser is bound or subject, (ii) any Laws or (iii) any
requirement of any Governmental or Regulatory Authority applicable to Purchaser,
or (c) except as set forth on Schedule 4.03 of the Disclosure Schedule, require
any filing, declaration or registration with, or permit, consent, approval,
waiver, clearance, order or authorization of, or the giving of any notice to,
any Governmental or Regulatory Authority or other Person.
4.04 Brokers and Finders. Purchaser has not employed any broker or
finder or incurred any liability for any brokerage fees, commissions or finders'
fees in connection with the transactions contemplated by this Agreement or the
Seller Documents. No Person is entitled to any fee, commission or like payment
in respect thereof based in any manner on any agreement, arrangement or
understanding made by or on behalf of Purchaser
4.05 Disclosure. The representations and warranties of Purchaser
contained in this Agreement do not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the
statements and information contained in this Agreement and in the Seller
Documents not misleading.
ARTICLE V
COVENANTS OF SELLER
Seller covenants and agrees with Purchaser that, at all times from and
after the date hereof until the Closing and, with respect to any covenant or
agreement by its terms to be performed in whole or in part after the Closing,
for the period specified herein or, if no period is specified herein,
indefinitely, Seller will comply with all covenants and provisions of this
Article V, except to the extent Purchaser may otherwise consent in writing.
5.01 Regulatory and Other Approvals. Seller will (a) take all
commercially reasonable steps necessary or desirable, and proceed diligently and
in good faith and use all commercially reasonable efforts, as promptly as
practicable to obtain all consents, approvals or actions of, to make all filings
with and to give all notices to Governmental or Regulatory Authorities or any
other Person required of Seller to consummate the transactions contemplated
hereby and by the Seller Documents, (b) provide such other information and
communications to such Governmental or Regulatory Authorities
-17-
<PAGE>
or other Persons as Purchaser or such Governmental or Regulatory Authorities or
other Persons may reasonably request in connection therewith and (c) cooperate
with Purchaser as promptly as practicable in obtaining all consents, approvals
or actions of, making all filings with and giving all notices to Governmental or
Regulatory Authorities or other Persons required of Purchaser to consummate the
transactions contemplated hereby and by the Seller Documents. Seller will
provide prompt notification to Purchaser when any such consent, approval,
action, filing or notice referred to in clause (a) above is obtained, taken,
made or given, as applicable, and will advise Purchaser of any communications
(and, unless precluded by Law, provide copies of any such communications that
are in writing) with any Governmental or Regulatory Authority or other Person
regarding any of the transactions contemplated by this Agreement or any of the
Seller Documents.
5.02 No Solicitations. Seller will not take, nor will it permit any
Affiliate of Seller (or authorize or permit any investment banker, financial
advisor, attorney, accountant or other Person retained by or acting for or on
behalf of Seller or any such Affiliate) to take, directly or indirectly, any
action to initiate, assist, solicit, receive, negotiate, encourage or accept any
offer or inquiry from any Person (a) to reach any agreement or understanding
(whether or not such agreement or understanding is absolute, revocable,
contingent or conditional) for, or otherwise attempt to consummate, the sale of
the Assets to any Person other than Purchaser or its Affiliates or (b) to
furnish or cause to be furnished any information with respect to the Assets to
any Person who Seller or such Affiliate (or any such Person acting for or on
their behalf) knows or has reason to believe is in the process of considering
any acquisition of the Assets. If Seller or any such Affiliate (or any such
Person acting for or on their behalf) receives from any Person any offer,
inquiry or informational request referred to above, Seller will promptly advise
such Person, by written notice, of the terms of this Section 5.02 and will
promptly, orally and in writing, advise Purchaser of such offer, inquiry or
request and deliver a copy of such notice to Purchaser.
5.03 Conduct relating to the Assets. Seller will operate and conduct
his business relating to the Assets only in the ordinary course consistent with
past practice such that, at the Closing, no representation, warranty, covenant,
obligation or agreement will be breached and no condition in this Agreement will
remain unfulfilled by reason of the actions or omissions of Seller. Without
limiting the generality of the foregoing, Seller will:
(a) use commercially reasonable efforts to (i) preserve intact
the present business organization and reputation of the business relating to the
Assets, (ii) maintain the Assets in good order and condition, and (iii) maintain
the goodwill of customers, suppliers, lenders and other Persons to whom Seller
sells goods or provides services or with whom Seller otherwise has significant
business relationships in connection with the Assets;
(b) except to the extent required by applicable Law, cause all
the Business Information to be maintained in the usual, regular and ordinary
manner;
-18-
<PAGE>
(c) not sell, assign, license, transfer or permit to lapse any
right or obligation with respect to the Intellectual Property, including but not
limited to making all filings required to be made with respect to and to
preserve all rights to the Intellectual Property; and
(d) comply, in all material respects, with all Laws applicable
to the Assets and promptly following receipt thereof to give Purchaser copies of
any notice received from any Governmental or Regulatory Authority or other
Person alleging any violation of any such Laws.
5.04 Licenses; Filings. As promptly as practicable, Seller will deliver
copies of all License applications and other filings made by Seller in
connection with the operation of the Assets after the date hereof and before the
Closing Date with any Governmental or Regulatory Authority.
5.05 Certain Restrictions. Seller will refrain from:
(a) acquiring or disposing of any of the Assets;
(b) entering into, amending, modifying, terminating (partially
or completely), granting any waiver under or giving any consent with respect to
any Contract or any License relating to the Assets;
(c) violating, breaching or defaulting under in any material
respect, or taking or failing to take any action that (with or without notice or
lapse of time or both) would constitute a material violation or breach of, or
default under, any term or provision of any Contract or License relating to the
Assets;
(d) incurring, purchasing, canceling, prepaying or otherwise
providing for a complete or partial discharge in advance of a scheduled payment
date with respect to, or waiving any right of Seller under, any liability of or
owing to Seller in connection with any of the Assets, other than in the ordinary
course of business consistent with past practice;
(e) entering into a mortgage, pledge or otherwise subjecting
to Lien any of the Assets;
(f) engaging with any Person in any merger, consolidation or
combination to which such Person is a party, any sale, dividend, split or other
disposition of capital stock or other equity interests of such Person or any
sale, dividend or other disposition of all or substantially all of the assets
and properties of such Person.
(g) engaging in any transaction with respect to the Assets
with any employee, debt-holder, officer, director, Affiliate or Associate of
Seller, or any Associate of any such employee, debt-holder, officer, director or
Affiliate, either outside the ordinary course of business consistent with past
practice or other than on an arm's-length basis;
-19-
<PAGE>
(h) entering into a contract which is deemed to be an Assigned
Contract; and
(i) entering into any Contract to do or engage in any of the
foregoing.
5.06 Delivery of Business Information. On the Closing Date, Seller will
deliver or make available to Purchaser at the location at which the Assets are
held all of the Business Information relating to the Assets which are or should
be in Seller's possession, and if at any time after the Closing Seller discovers
in his possession or under his control any other Business Information or other
Assets, it will forthwith deliver such Business Information or other Assets to
Purchaser.
5.07 Non-competition.
(a) Seller will, for a period of ten years from the Closing
Date, refrain from, either alone or in conjunction with any other Person, or
directly or indirectly through his present or future Affiliates:
(i) causing or attempting to cause any client,
customer or supplier of Purchaser to terminate or materially
reduce its business with Purchaser or any of its Affiliates
relating to the Assets; or
(ii) participating or engaging in (other than through
the ownership of five percent or less of any class of
securities registered under the Securities Exchange Act of
1934, as amended), or otherwise lending assistance (financial
or otherwise) to any Person participating or engaged in, any
business relating to the Assets.
(b) The parties hereto recognize that the Laws and public
policies of the various states of the United States may differ as to the
validity and enforceability of covenants similar to those set forth in this
Section. It is the intention of the parties that the provisions of this Section
be enforced to the fullest extent permissible under the Laws and policies of
each jurisdiction in which enforcement may be sought, and that the
unenforceability (or the modification to conform to such Laws or policies) of
any provisions of this Section shall not render unenforceable, or impair, the
remainder of the provisions of this Section. Accordingly, if any provision of
this Section shall be determined to be invalid or unenforceable, such invalidity
or unenforceability shall be deemed to apply only with respect to the operation
of such provision in the particular jurisdiction in which such determination is
made and not with respect to any other provision or jurisdiction.
(c) The parties hereto acknowledge and agree that any remedy
at Law for any breach of the provisions of this Section would be inadequate, and
Seller hereby consents to the granting by any court of an injunction or other
equitable relief, without the necessity of actual monetary loss being proved, in
order that the breach or threatened breach of such provisions may be effectively
restrained.
-20-
<PAGE>
5.08 Notice and Cure. Seller will notify Purchaser in writing (where
appropriate, through updates to the Disclosure Schedule) of, and
contemporaneously will provide Purchaser with true and complete copies of any
and all information or documents relating to, and will use all commercially
reasonable efforts to cure before the Closing, any event, transaction or
circumstance, as soon as practicable after it becomes known, or reasonably
should have become known, to Seller, occurring after the date of this Agreement,
that causes or will cause any covenant or agreement of Seller under this
Agreement to be breached or that renders or will render untrue any
representation or warranty of Seller contained in this Agreement as if the same
were made on or as of the date of such event, transaction or circumstance.
Seller also will notify Purchaser in writing (where appropriate, through updates
to the Disclosure Schedule) of, and will use all commercially reasonable efforts
to cure, before the Closing, any violation or breach, as soon as practicable
after it becomes known, or reasonably should have become known, to Seller, of
any representation, warranty, covenant or agreement made by Seller in this
Agreement, whether occurring or arising before, on or after the date of this
Agreement. No notice given pursuant to this Section shall have any effect on the
representations, warranties, covenants or agreements contained in this Agreement
for purposes of determining satisfaction of any condition contained herein or
shall in any way limit Purchaser's right to seek indemnity under Article X.
5.09 Fulfillment of Conditions. Seller will execute and deliver at the
Closing each of the Seller Documents that Seller is required hereby to execute
and deliver as a condition to the Closing, will take all commercially reasonable
steps necessary or desirable and proceed diligently and in good faith to satisfy
each other condition to the obligations of Purchaser contained in this Agreement
and will not take or fail to take any action that could reasonably be expected
to result in the nonfulfillment of any such condition.
ARTICLE VI
COVENANTS OF PURCHASER
Purchaser covenants and agrees with Seller that, at all times from and
after the date hereof until the Closing, and, with respect to any covenant or
agreement by its terms to be performed in whole or in part after the Closing,
for the period specified herein or, if no period is specified herein,
indefinitely, Purchaser will comply with all covenants and provisions of this
Article VI, except to the extent Seller may otherwise consent in writing.
6.01 Regulatory and Other Approvals. Purchaser will (a) take
commercially reasonable steps necessary or desirable, and proceed diligently and
in good faith and use commercially reasonable efforts, as promptly as
practicable to obtain all consents, approvals or actions of, to make all filings
with and to give all notices to Governmental or Regulatory Authorities or any
other Person required of Purchaser to consummate the transactions contemplated
hereby and by the Seller Documents, (b) provide such other information and
communications to such Governmental or Regulatory Authorities or other Persons
as Seller or such Governmental or Regulatory Authorities or other Persons may
-21-
<PAGE>
reasonably request in connection therewith and (c) cooperate with Seller as
promptly as practicable in obtaining all consents, approvals or actions of,
making all filings with and giving all notices to Governmental or Regulatory
Authorities or other Persons required of Seller to consummate the transactions
contemplated hereby and by the Seller Documents. Purchaser will provide prompt
notification to Seller when any such consent, approval, action, filing or notice
referred to in clause (a) above is obtained, taken, made or given, as
applicable, and will advise Seller of any communications (and, unless precluded
by Law, provide copies of any such communications that are in writing) with any
Governmental or Regulatory Authority or other Person regarding any of the
transactions contemplated by this Agreement or any of the Seller Documents.
6.02 Notice and Cure. Purchaser will notify Seller in writing of, and
contemporaneously will provide Seller with true and complete copies of any and
all information or documents relating to, and will use all commercially
reasonable efforts to cure before the Closing, any event, transaction or
circumstance, as soon as practicable after it becomes known, or reasonably
should have become known, to Purchaser, occurring after the date of this
Agreement, that causes or will cause any covenant or agreement of Purchaser
under this Agreement to be breached or that renders or will render untrue any
representation or warranty of Purchaser contained in this Agreement as if the
same were made on or as of the date of such event, transaction or circumstance.
Purchaser also will notify Seller in writing of, and will use all commercially
reasonable efforts to cure, before the Closing, any violation or breach, as soon
as practicable after it becomes known, or reasonably should have become known,
to Purchaser, of any representation, warranty, covenant or agreement made by
Purchaser in this Agreement, whether occurring or arising before, on or after
the date of this Agreement. No notice given pursuant to this Section shall have
any effect on the representations, warranties, covenants or agreements contained
in this Agreement for purposes of determining satisfaction of any condition
contained herein or shall in any way limit Seller's right to seek indemnity
under Article X.
6.03 Delivery of Documents. Purchaser will execute and deliver to
Seller the Subscription Agreement, the Registration Rights Agreement and the
Warrant.
6.04 Fulfillment of Conditions. Purchaser will take all commercially
reasonable actions necessary or desirable and proceed diligently and in good
faith to satisfy each other condition to the obligations of Seller contained in
this Agreement and will not take or fail to take any action that could
reasonably be expected to result in the nonfulfillment of any such condition.
ARTICLE VII
CONDITIONS TO OBLIGATIONS OF SELLER
The obligations of Seller hereunder are subject to the fulfillment, at
or before the Closing, of each of the following conditions (all or any of which
may be waived in whole or in part by Seller in his sole discretion):
-22-
<PAGE>
7.01 Representations, Warranties and Covenants. Each of the
representations and warranties made by Purchaser in this Agreement shall be true
and correct in all material respects on the date hereof and on the Closing Date
as though such representation or warranty was made on and as of the Closing
Date.
7.02 Performance. Purchaser shall have performed and complied with each
agreement, covenant and obligation required by this Agreement to be so performed
or complied with by Purchaser at or before the Closing.
7.03 Laws. There shall not be in effect on the Closing Date any Law
that became effective after the date of this Agreement restraining, enjoining or
otherwise prohibiting or making illegal the consummation of any of the
transactions contemplated by this Agreement or any of the Seller Documents.
7.04 Officer's Certificate. Purchaser shall have delivered to Seller a
certificate, dated the Closing Date and executed by an officer of Purchaser,
certifying resolutions of Purchaser's Board of Directors authorizing the
execution, delivery and performance of this Agreement, together with incumbency
and a signature certificate regarding the officer signing on Purchaser's behalf.
7.05 Regulatory Consents and Approvals. All consents, approvals and
actions of, filings with and notices to any Governmental or Regulatory Authority
necessary to permit Seller and Purchaser to perform their obligations under this
Agreement and the Operative Agreements and to consummate the transactions
contemplated hereby and thereby (a) shall have been duly obtained, made or
given, (b) shall be in form and substance reasonably satisfactory to Seller (c)
shall not be subject to the satisfaction of any condition that has not been
satisfied or waived and (d) shall be in full force and effect, and all
terminations or expirations of waiting periods imposed by any Governmental or
Regulatory Authority necessary for the consummation of the transactions
contemplated by this Agreement and the Seller Documents, shall have occurred.
7.06 Opinion of Counsel. Seller shall have received the opinion of
Parker Chapin Flattau & Klimpl, LLP, counsel to Purchaser, dated the Closing
Date, substantially in the form and to the effect of Exhibit H hereto.
7.07 Delivery of Documents. At the Closing, Purchaser shall execute and
deliver to Seller the documents described in Section 2.05(b).
7.08 Proceedings. All proceedings to be taken on the part of Purchaser
in connection with the transactions contemplated by this Agreement and all
documents incident thereto shall be reasonably satisfactory in form and
substance to Seller, and Seller shall have received copies of all such documents
and other evidences as Seller may reasonably request in order to establish the
consummation of such transactions and the taking of all proceedings in
connection therewith.
-23-
<PAGE>
ARTICLE VIII
CONDITIONS TO OBLIGATIONS OF PURCHASER
The obligations of Purchaser hereunder are subject to the fulfillment,
at or before the Closing, of each of the following conditions (all or any of
which may be waived in whole or in part by Purchaser in its sole discretion):
8.01 Representations, Warranties and Covenants. Each of the
representations and warranties made by Seller in this Agreement (other than
those made as of a specified date earlier than the Closing Date) shall be true
and correct in all material respects on and as of the Closing Date as though
such representation or warranty was made on the date hereof and on the Closing
Date, and any representation or warranty made as of a specified date earlier
than the Closing Date shall have been true and correct in all material respects
on and as of such specified date.
8.02 Performance. Seller shall have performed and complied with each
agreement, covenant and obligation required by this Agreement to be so performed
or complied with by Purchaser at or before the Closing.
8.03 Laws. There shall not be in effect on the Closing Date any Law
restraining, enjoining or otherwise prohibiting or making illegal the
consummation of any of the transactions contemplated by this Agreement or any of
the Seller Documents, or which could reasonably be expected to otherwise result
in a material diminution of the benefits of the transactions contemplated by
this Agreement or any of the Seller Documents to Purchaser, and there shall not
be pending or threatened on the Closing Date any Action or Proceeding or any
other action in, before or by any Governmental or Regulatory Authority which
could reasonably be expected to result in the issuance of any such Order or the
enactment, promulgation or deemed applicability to Purchaser or the transactions
contemplated by this Agreement or any of the Seller Documents of any such Law.
8.04 Regulatory Consents and Approvals. All consents, approvals and
actions of, filings with and notices to any Governmental or Regulatory Authority
necessary to permit Purchaser and Seller to perform their obligations under this
Agreement and any of the Seller Documents and to consummate the transactions
contemplated hereby and thereby (a) shall have been duly obtained, made or
given, (b) shall be in form and substance reasonably satisfactory to Purchaser,
(c) shall not be subject to the satisfaction of any condition that has not been
satisfied or waived and (d) shall be in full force and effect, and all
terminations or expirations of waiting periods imposed by any Governmental or
Regulatory Authority necessary for the consummation of the transactions
contemplated by this Agreement and the Seller Documents shall have occurred.
8.05 Third Party Consents. All consents (or in lieu thereof waivers) to
the performance by Seller of his obligations under this Agreement and the Seller
Documents or to the consummation of the transactions contemplated hereby and
thereby as are required under any Contract to which Seller is a party or by
which any of the Assets are bound (a) shall have been obtained, (b) shall be in
form
-24-
<PAGE>
and substance reasonably satisfactory to Purchaser, (c) shall not be subject to
the satisfaction of any condition that has not been satisfied or waived and (d)
shall be in full force and effect.
8.06 Delivery of Assets and Documents. At the Closing, Seller shall
deliver all the Assets to Purchaser and execute and deliver to Purchaser all the
documents required to be delivered by Seller as set forth in Section 2.05(c) and
such additional documents as may be necessary in order to consummate the
transactions contemplated by this Agreement and the Seller Documents.
8.07 Opinion of Counsel. Purchaser shall have received the opinion of
Lagerlof, Senecal, Bradley, Gosney & Kruse, LLP, counsel to Seller, dated the
Closing Date, substantially in the form and to the effect of Exhibit I hereto.
8.08 Tax Status. Purchaser shall have received evidence of payment,
including tax clearance certificates, of all sales, use, transfer, value-added
or other Taxes that are to be paid by Seller on or before the Closing in
Pennsylvania and any other applicable jurisdictions.
8.09 Proceedings. All proceedings to be taken on the part of Seller in
connection with the transactions contemplated by this Agreement and all
documents incident thereto shall be reasonably satisfactory in form and
substance to Purchaser, and Purchaser shall have received copies of all such
documents and other evidences as Purchaser may reasonably request in order to
establish the consummation of such transactions and the taking of all
proceedings in connection therewith.
ARTICLE IX
ADDITIONAL POST-CLOSING COVENANTS
9.01 Further Assurances, Post-Closing Cooperation.
(a) At any time or from time to time after the Closing, at
Purchaser's request and without further consideration, Seller shall execute and
deliver to Purchaser such other instruments of sale, transfer, conveyance,
assignment and confirmation, provide such materials and information and take
such other actions as Purchaser may reasonably deem necessary or desirable in
order more effectively to transfer, convey and assign to Purchaser, and to
confirm Purchaser's title to, all of the Assets, and, to the fullest extent
permitted by Law, to put Purchaser in actual possession and operating control of
the Assets and to assist Purchaser in exercising all rights with respect
thereto, and otherwise to cause Seller to fulfill his obligations under this
Agreement, including but not limited to, filings with any regulatory agencies to
be made by Seller alone, or by Seller and Purchaser jointly.
(b) At any time or from time to time after the Closing, at
Seller's request and without further consideration, Purchaser shall execute and
deliver to Seller such other instruments, provide such materials and information
and take such other actions as Purchaser may reasonably
-25-
<PAGE>
deem necessary or desirable in order to give effect to Purchaser's assumption of
the Assumed Liabilities.
(c) Effective on the Closing Date, Seller hereby constitutes
and appoints Purchaser the true and lawful attorney of Seller, with full power
of substitution, in the name of Seller or Purchaser, but on behalf of and for
the benefit of Purchaser; (i) to demand and receive from time to time any and
all the Assets and to make endorsements and give receipts and releases for and
in respect of the same and any part thereof; (ii) to institute, prosecute,
compromise and settle any and all Actions or Proceedings that Purchaser may deem
proper in order to collect, assert or enforce any claim, right or title of any
kind in or to the Assets, (iii) to defend or compromise any or all Actions or
Proceedings in respect of any of the Assets; and (iv) to do all such acts and
things in relation to the matters set forth in the preceding clauses (i) through
(iii) as Purchaser shall deem desirable. Seller hereby acknowledges that the
appointment hereby made and the powers hereby granted are coupled with an
interest and are not and shall not be revocable by it at any time, in any manner
or for any reason. Seller shall deliver to Purchaser at Closing an acknowledged
power of attorney to the foregoing effect executed by Seller substantially in
the form and to the effect of Exhibit J hereto. Purchaser shall indemnify and
hold harmless Seller and his agents and Affiliates from any and all Losses
caused by or arising out of any breach of Law by Purchaser in its exercise of
such power of attorney.
(d) For a period of six (6) years following the Closing, each
party will afford the other party, its counsel and its accountants, during
normal business hours, reasonable access to the books, records and other data
relating to the Assets in its possession with respect to periods prior to the
Closing and the right to make copies and extracts therefrom, to the extent that
such access may be reasonably required by the requesting party in connection
with (i) the preparation of Tax returns, (ii) the determination or enforcement
of rights and obligations under this Agreement, (iii) compliance with the
requirements of any Governmental or Regulatory Authority, (iv) the determination
or enforcement of the rights and obligations of any Indemnified Party or (v) in
connection with any actual or threatened Action or Proceeding. Further each
party agrees for a period extending six years after the Closing Date not to
destroy or otherwise dispose of any such books, records and other data relating
to the Assets unless such party shall first offer in writing to surrender such
books, records and other data to the other party and such other party shall not
agree in writing to take possession thereof during the ten day period after such
offer is made.
(e) If, in order properly to prepare its Tax returns, other
documents or reports required to be filed with Governmental or Regulatory
Authorities or its financial statements or to fulfill its obligations hereunder,
it is necessary that a party be furnished with additional information, documents
or records relating to the Assets not referred to in paragraph (c) above, and
such information, documents or records are in the possession or control of the
other party, such other party shall use its best efforts to furnish or make
available such information, documents or records (or copies thereof) at the
recipient's request, cost and expense. Any information obtained by either party
in accordance with this paragraph shall be held confidential by such party in
accordance with Section 12.12.
-26-
<PAGE>
(f) Notwithstanding anything to the contrary contained in this
section, if the parties are in an adversarial relationship in litigation or
arbitration, the furnishing of information, documents or records in accordance
with this section shall be subject to applicable rules relating to discovery.
9.02 FDA Approvals. Within seven days after the Closing Date, both
Purchaser and Seller will inform FDA of the ownership transfer of the Assets if
required by Law.
9.03 Adverse Drug Experience; Recalls. Seller shall notify Purchaser of
all material information of which Seller becomes aware concerning side effects,
injury, toxicity or sensitivity reactions including incidence and severity
thereof associated with commercial or clinical uses, studies, investigations or
tests of any products relating to the Assets, whether or not determined to be
attributable to such products, which may constitute an adverse drug experience
with respect to such products under any Laws. Seller shall notify Purchaser of
any complaints of which Seller becomes aware concerning any of the Technology or
products relating to the Assets.
9.04 Delivery of Shares. As soon as practicable after the Closing Date,
upon Seller entering into the Subscription Agreement and the Registration Rights
Agreement and upon receipt of all authorizations, Purchaser will deliver the
Shares to Seller.
9.05 Non-Assertion of Patent. Seller agrees to not assert the 303
Patent or any other patent which has one or more claims that are directed to
subject matter which is disclosed in the 303 Patent and that refer to a
composition which contains a skin-treating compound (as defined in the 303
Patent) against the Purchaser of the U.S. Patent, or assignee or licensee
thereof, or any customer of the Purchaser, assignee or licensee (hereafter
collectively referred to as "Section 9.05 Person") in connection with the
manufacture, use or sale by a Section 9.05 Person of a composition which is
within the scope of any claim of the U.S. Patent and which is sold only for a
pharmaceutical industry application, notwithstanding that such composition may
also enhance one or more properties of skin as described in the 303 Patent,
beginning at column 22, line 11.
ARTICLE X
INDEMNIFICATION
10.01 Survival of Representations, Warranties, Covenants and
Agreements. Notwithstanding any right of Purchaser fully to investigate the
affairs of Seller or any other party and notwithstanding any knowledge of the
facts determined or determinable by Purchaser pursuant to such investigation or
right of investigation, Purchaser has the right to rely fully upon the
representations, warranties, covenants and agreements of Seller contained in
this Agreement and the Seller Documents. All such representations warranties,
covenants and agreements of Seller made in this Agreement and the Seller
Documents delivered pursuant hereto shall survive the execution and delivery
hereof and the Closing.
-27-
<PAGE>
10.02 Purchaser's Indemnified Liabilities. Seller hereby agrees to
indemnify Purchaser, its directors, officers, employees, agents and Affiliates
against any liability and will hold each of them harmless from, against and with
respect to, and will reimburse, any Loss which Purchaser, its directors,
officers, employees, agents and Affiliates incur, sustain or suffer
("Purchaser's Indemnified Liabilities") arising out of or in connection with:
(a) Seller's misrepresentation, breach of any representation,
warranty, agreement or covenant or nonfulfillment of or failure to perform any
covenant or agreement on the part of Seller contained in this Agreement or in
the Seller Documents;
(b) the Retained Liabilities;
(c) any liability for Taxes arising out of operations of
Seller relating to the Assets on or prior to the Closing or arising from the
sale consummated hereunder;
(d) any actual or alleged liability or obligation of Seller
arising out of the ownership or operation of the Assets on or prior to the
Closing;
(e) any litigation matter to which Seller, in connection with
the Assets, or the Assets were subject to on or prior to the Closing; or
(f) any liability, loss of any of the Assets or other recovery
resulting from or relating to any litigation or other proceeding commenced by or
involving Conrex, its officers, directors, shareholders or Affiliates, which
relates to the validity of the sale of the Assets from Conrex to Seller.
10.03 Seller's Indemnified Liabilities. Purchaser hereby agrees to
indemnify Seller, his employees, agents and Affiliates against any liability and
will hold each of them harmless from, against and with respect to, and will
reimburse, any Loss which Seller, his employees, agents and Affiliates incur,
sustain or suffer ("Seller's Indemnified Liabilities") arising out of or in
connection with:
(a) Purchaser's misrepresentation, breach of any
representation, warranty, agreement or covenant or nonfulfillment of or failure
to perform any covenant or agreement on the part of Purchaser contained in this
Agreement;
(b) the Assumed Liabilities; or
(c) any actual or alleged liability or obligation of Purchaser
arising out of the ownership or operation of the Assets after the Closing.
10.04 Notice and Defense of a Claim. If either party shall be presented
with or have actual notice of a claim against it which gives or may give rise to
an Indemnified Liability, then the party
-28-
<PAGE>
entitled to indemnification (the "Indemnified Party") shall notify the other
(the "Indemnifying Party") in writing thereof (in accordance with Section 12.01)
within thirty days of notice of a claim, otherwise the Indemnified Party shall
waive its right to seek indemnification hereunder. The Indemnifying Party may,
at its expense, vigorously and diligently prosecute, defend and settle any such
claim; and if the Indemnifying Party assumes such defense it will notify the
Indemnified Party thereof, and thereafter the Indemnifying Party will not,
except as provided below, be obligated to pay any expenses of the Indemnified
Party (including but not limited to, legal fees and disbursements, court costs
and the cost of appellate proceedings) in connection with such claim, provided,
however, that the Indemnified Party may, at the sole cost and expense of the
Indemnified Party, at any time prior to the Indemnifying Party's delivery of the
notice referred to above, file any motion, answer or other pleadings or take any
other action that the Indemnified Party reasonably believes to be necessary or
appropriate to protect its interests. The Indemnified Party will cooperate in
the defense of any such claim, and the Indemnifying Party will pay any costs
incurred by the Indemnified Party in connection therewith. The Indemnified Party
will not settle any claims for which the Indemnifying Party may be liable
without the prior written consent of the Indemnifying Party unless (i) the
Indemnified Party releases the Indemnifying Party from all of the Indemnifying
Party's obligations to the Indemnified Party with respect to the claim, or (ii)
the Indemnifying Party is in default in its obligations under this Section. In
the case of a settlement pursuant to item (ii), the Indemnifying Party will
promptly pay to or in accordance with the instructions of the Indemnified Party
any amount payable pursuant to such settlement. Notwithstanding the foregoing,
if both the Indemnifying Party and the Indemnified Party are named as parties or
subject to any claim and either such party determines with advice of counsel and
in its reasonable discretion that there may be one or more legal defenses
available to it that are different from or additional to those available to the
other party or that a conflict of interest between such parties may exist in
respect of such claim, then the Indemnifying Party may decline to assume the
defense on behalf of the Indemnified Party or the Indemnified Party may retain
the defense on its own behalf, and, in either such case, after notice to such
effect is duly given to the other party (in accordance with Section 12.01), the
Indemnifying Party shall be relieved of its obligation to assume the defense on
behalf of the Indemnified Party, but shall be required to pay any legal or other
expenses, including without limitation, reasonable attorneys' fees and
disbursements, incurred by the Indemnified Party in its defense.
ARTICLE XI
TERMINATION
11.01 Termination. This Agreement and the Seller Documents may be
terminated, and the transactions contemplated hereby and thereby may be
abandoned:
(a) at any time before the Closing, by written agreement of
Seller and Purchaser;
(b) at any time before the Closing, by Seller or Purchaser, in
the event (i) of a material breach hereof by the non-terminating party if such
non-terminating party fails to cure such
-29-
<PAGE>
breach within five Business Days following written notification thereof by the
terminating party or (ii) upon written notification of the non-terminating party
by the terminating party that the satisfaction of any condition to the
terminating party's obligations under this Agreement or the Seller Documents
becomes impossible or impracticable with the use of commercially reasonable
efforts if the failure of such condition to be satisfied is not caused by a
breach hereof by the terminating party; or
(c) at any time after March 15, 1999 by Seller or Purchaser
upon written notification to the non-terminating party by the terminating party
if the Closing shall not have occurred on or before such date and such failure
to consummate is not caused by a breach of this Agreement or the Seller
Documents by the terminating party.
11.02 Effect of Termination.
(a) If this Agreement and the Seller Documents are validly
terminated pursuant to Section 11.01, this Agreement and the Seller Documents
will immediately become null and void, and there will be no liability or
obligation on the part of Seller or Purchaser (or any of their respective
officers, directors, employees, agents or other representatives or Affiliates);
provided, however, that if this Agreement is terminated for any reason other
than Seller's material breach or failure to satisfy a condition, Seller shall
refund the $50,000 due diligence deposit paid by Purchaser pursuant to the
letter agreement between the parties dated November 23, 1998. In the event of
any termination, the provisions with respect to "Expenses" in Section 12.05,
"Entire Agreement" in Section 12.06 and "Confidentiality" in Section 12.12 will
continue to apply following any such termination.
(b) Notwithstanding any other provision in this Agreement to
the contrary, upon termination of this Agreement pursuant to Section 11.01(b) or
(c), Seller will remain liable to Purchaser for any breach of this Agreement by
Seller existing at the time of such termination, and Purchaser will remain
liable to Seller for any breach of this Agreement by Purchaser existing at the
time of such termination, and Seller or Purchaser may seek such remedies,
including damages and fees of attorneys, against the other with respect to any
such breach as are provided in this Agreement or as are otherwise available at
Law or in equity.
ARTICLE XII
MISCELLANEOUS
12.01 Notices. All notices, demands or other communications to be given
or delivered under or by reason of the provisions of this Agreement shall be in
writing and shall be deemed to have been given (a) when delivered personally to
the recipient, (b) when sent to the recipient by telecopy (receipt
electronically confirmed by sender's telecopy machine) if during normal business
hours of the recipient, otherwise on the next Business Day, (c) one Business Day
after the date when sent to the recipient by reputable express courier service
(charges prepaid) or (d) seven Business Days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage
-30-
<PAGE>
prepaid. Such notices, demands and other communications will be sent to Seller
and to Purchaser at the addresses indicated below:
If to Purchaser: Bentley Pharmaceuticals, Inc
Two Urban Centre
Suite 400
4830 West Kennedy Blvd.
Tampa, Florida 33609
Attention: James R. Murphy
Facsimile No.: (813) 282-8941
With a copy (which shall Parker, Chapin, Flattau & Klimpl, LLP
not constitute notice) to: 1211 Avenue of the Americas
New York, New York 10036
Attention: Jordan A. Horvath and Mark S. Hirsch
Facsimile No.: (212) 704-6288
If to Seller: Yungtai Hsu
Facsimile No.:
With a copy (which shall not
constitute notice) to: Lagerlof, Senecal, Bradley, Gosney & Kruse, LLP
301 North Lake Avenue, 10th Floor
Pasadena, CA 91101
Attention: Timothy J. Gosney
Facsimile No.: (626) 793-5900
or to such other address as any party hereto may, from time to time, designate
in writing delivered pursuant to the terms of this Section.
12.02 Amendments. The terms, provisions and conditions of this
Agreement may not be changed, modified or amended in any manner except by an
instrument in writing duly executed by both parties hereto.
12.03 Binding Effect; Assignment. This Agreement and the rights and
obligations hereunder are assignable by Purchaser and any such assignment shall
be binding in all respects on Seller, as if Seller had sold all or part of the
Assets directly to the assignee. This Agreement shall be binding upon and shall
inure to the benefit of the parties hereto and their respective successors and
permitted assigns.
-31-
<PAGE>
12.04 Announcements. All press releases, notices to customers and
suppliers and other announcements prior to the Closing Date with respect to this
Agreement and the Seller Documents and the transactions contemplated by this
Agreement and the Seller Documents shall be approved by both Purchaser and
Seller prior to the issuance thereof, which approval shall not be unreasonably
withheld or delayed; provided that any party may make any public disclosure it
believes in good faith is required by law or regulation (in which case the
disclosing party shall advise the other party prior to making such disclosure
and provide such other party an opportunity to review the proposed disclosure).
12.05 Expenses. Except as otherwise set forth in this Agreement, each
party to this Agreement shall bear all of its legal, accounting and other
expenses incurred by it or on its behalf in connection with the transactions
contemplated by this Agreement, whether or not such transactions are
consummated.
12.06 Entire Agreement. This Agreement and the Seller Documents
constitute the entire agreement between the parties hereto with respect to the
subject matter hereof and supersede and are in full substitution for any and all
prior agreements, commitments, discussions, negotiations, arrangements or
understandings between the parties relating to such subject matter, including,
but not limited to, any letters of intent between the parties prior to the date
hereof. The Seller Documents, including but not limited to the Exhibits and
Schedules to this Agreement, are hereby incorporated and made a part hereof and
are an integral part of this Agreement.
12.07 Descriptive Headings. The descriptive headings of the several
sections of this Agreement are inserted for convenience only and shall not
control or affect the meaning or construction of any of the provisions hereof.
12.08 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
12.09 Governing Law; Jurisdiction. This agreement shall be governed by,
and interpreted and enforced in accordance with, the laws of the State of New
York without regard to principles of choice of law or conflict of laws.
12.10 Arbitration of Disputes
(a) If any controversy or dispute arises under, out of or in
relation to any of the provisions hereof, such controversy or dispute shall be
submitted for arbitration in New York, New York before a panel of three
arbitrators, one of which shall be selected by the party initiating such
arbitration, one of which shall be selected by the other party and the third of
which (the "Third Arbitrator") shall be selected by the two arbitrators so
selected; provided, however, that in the event that such other arbitrators shall
not agree on the selection of the Third Arbitrator, the Third Arbitrator
-32-
<PAGE>
shall be selected by the American Arbitration Association located in New York,
New York. Any dispute or controversy submitted to arbitration in accordance with
the provisions of this Section 12.10 shall be determined by such arbitrators in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association then existing.
(b) The arbitrators may award any relief which they shall deem
proper in the circumstances, without regard to the relief which would otherwise
be available to any party in a court of law or equity including, without
limitation, an award of money damages, specific performance, injunctive relief
and/or declaratory relief, however, such an award may not include punitive
damages. The award and findings of the arbitrators shall be conclusive and
binding upon all of the parties hereto, whether or not all parties hereto
participate in the arbitration proceeding, and judgment upon the award may be
entered in any court of competent jurisdiction upon the application of any
party. The parties hereby agree that such courts of competent jurisdiction shall
include, but not be limited to, the courts located in any jurisdiction in which
the party against whom such judgment is being enforced maintains any assets.
(c) The prevailing party in the arbitration proceeding shall
be entitled to recover from the other party its reasonable attorneys' fees,
costs and expenses incurred in the proceeding and in any subsequent action to
enforce or collect upon the decision rendered in the arbitration proceeding.
(d) Notwithstanding the foregoing, the parties reserve the
right to seek and obtain injunctive relief, whether in the form of a temporary
restraining order, preliminary injunction, injunction to enforce an arbitration
award, or other order of similar import, from the federal and state courts
located in New York, New York prior to, during, or after commencement or
prosecution or arbitration proceedings of the final decision and award of the
arbitrators; provided, however, that such preliminary injunctive relief shall be
subject to final arbitral decisions.
(e) Each party hereby consents and agrees that the federal and
state courts located in New York, New York each shall have exclusive personal
jurisdiction and proper venue with respect to any such action seeking injunctive
or similar relief hereunder. In any dispute between the parties, neither party
will raise, and each party hereby expressly waives, any objection or defense to
any such court as an inconvenient forum. Each party hereby waives personal
service of any summons, complaint or other process, which may be delivered by
any of the means permitted for notices under Section 12.01 hereof
12.11 Severability. In the event that any one or more of the provisions
contained in this Agreement or in any other instrument referred to herein shall,
for any reason, be held to be invalid, illegal or unenforceable in any respect,
then to the maximum extent permitted by law, such invalidity, illegality or
unenforceability shall not affect any other provision of this Agreement or any
other such instrument. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part
of this Agreement a provision as similar in terms to such invalid or
unenforceable provision as may be possible and be valid and enforceable.
-33-
<PAGE>
12.12 Confidentiality. Seller and Purchaser agree to keep, and to cause
each of their Affiliates, directors, officers and employees to keep,
confidential any and all confidential information of the other party that either
receives in the course of performing its obligations hereunder (unless compelled
by judicial or administrative process and except that such information may be
shared, on a confidential basis, with the party's attorneys and auditors) and
will not, without the other party's written consent, use any of such
confidential information except as reasonably necessary to perform its duties
under this or another of its agreements with the other party (for purposes of
this Agreement, "confidential information" includes any and all trade secrets
(including information relating to the Technology, the Patents and the Business
Information), financial information not disclosed to the general public and
other proprietary information disclosed in the course of the negotiation of this
Agreement and Purchaser's due diligence investigation). Furthermore, Seller
agrees to refrain from, either alone or in conjunction with any other Person,
directly or indirectly through his present or future Affiliates, and agrees to
cause his Affiliates and employees to refrain from disclosing or using any
Business Information relating to the Assets or the Technology or any client,
customer or supplier of the Assets or the Technology. Upon termination of this
Agreement, each party will return, and will cause its Affiliates, directors,
officers and employees to return, to the other party, all original documents and
copies of the confidential information which are in its possession.
-34-
<PAGE>
IN WITNESS WHEREOF, Seller and Purchaser have executed and
delivered this Agreement as of the day and year first written above.
/s/ Yungtai Hsu
-------------------------------------
Yungtai Hsu, in his personal capacity
BENTLEY PHARMACEUTICALS, INC.
By: /s/ James R. Murphy
-----------------------------------
James R. Murphy, Chairman and Chief
Executive Officer
-35-
SUBSCRIPTION AGREEMENT
----------------------
BENTLEY PHARMACEUTICALS, INC.
-----------------------------
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
February 11, 1999
Dear Sir or Madam:
Upon the terms and subject to the conditions of an Asset
Purchase Agreement, dated February 1, 1999 effective as of December 31, 1998
(the "Asset Purchase Agreement"), between Bentley Pharmaceuticals, Inc. (the
"Company") and Yungtai Hsu ("Hsu"), in which Hsu agreed to sell certain of his
assets to the Company, Hsu has agreed to accept as part of the Purchase Price
(as defined in the Asset Purchase Agreement) (a) 225,807 shares (the "Shares")
of common stock, $0.02 par value per share (the "Common Stock") of the Company,
and (b) a warrant to purchase 450,000 shares of Common Stock (the "Warrant",
collectively the Shares and the Warrant, the "Securities"). Therefore, in
consideration of the premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, Hsu hereby agrees to:
1. Subscription. Hsu hereby applies to subscribe for the
Securities. Once this Agreement is executed by both Hsu and the Company, it is
intended to create a binding agreement between Hsu and the Company with respect
to the terms and conditions described below.
2. Representations and Warranties of Hsu. Hsu acknowledges,
represents, warrants and agrees as follows:
(a) Authorization. Hsu has full power and
legal capacity to execute and deliver this Agreement. This Agreement has been
duly executed and delivered by Hsu and, assuming the execution and delivery
hereof and thereof by the Company, will constitute the legal, valid and binding
obligations of Hsu, enforceable against Hsu in accordance with its terms, except
as the same may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting the rights of creditors generally and
the availability of equitable remedies.
<PAGE>
(b) Accredited Investor. Hsu is an
accredited investor (as defined in Rule 501 of Regulation D ("Regulation D")
promulgated under the Securities Act of 1933, as amended (the "Act"). Hsu has
such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of, and bearing the economic risks entailed
by, an investment in the Company and of protecting his interests in connection
with this transaction. Hsu recognizes that his investment in the Company
involves certain risks which are set forth in the Company's Registration
Statement on Form S-3 (SEC File No. 333-28593, the "Registration Statement" )
declared effective by the Securities and Exchange Commission on June 10, 1997
and any amendments thereto.
(c) Due Diligence. Hsu has received a copy
of such documents as requested by him, has carefully reviewed such documents,
has had the opportunity to obtain any additional information necessary to verify
the accuracy of the information contained in such documents and has been given
the opportunity to meet with representatives of the Company and to have them
answer any questions and provide any additional information regarding the terms
and conditions of this particular investment deemed relevant by Hsu, and all
such questions have been answered and requested information provided to Hsu's
full satisfaction. Among the documents received and reviewed by Hsu are: (i) the
Company's Annual Report on Form 10-K for the year ended December 31, 1997; (ii)
the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31,
1998, June 30, 1998 and September 30, 1998 (such documents are collectively
referred to in this Agreement as the "Exchange Act Reports"); (iii) the
Registration Statement and (iv) a Registration Rights Agreement between the
Company and Hsu with respect to the Shares, dated as of the date hereof (the
"Registration Rights Agreement.") In making his decision to accept the
Securities as part of the Purchase Price, Hsu has relied solely upon his review
of the documents referred to above and this Agreement and independent
investigations made by him or his representatives.
(d) No Legal Advice from the Company. Hsu
acknowledges that he has had the opportunity to review this Agreement and the
transactions contemplated by this Agreement with his own legal counsel and tax
advisors. Except for any statements or representations of the Company made in
this Agreement, in the Exchange Act Reports and in the Registration Rights
Agreement, Hsu is relying solely on such counsel and advisors and not on any
statements or representations of the Company or any of its representative or
agents for legal, tax or investment advice with respect to this investment, the
transactions contemplated by this Agreement or the securities laws of any
jurisdiction.
(e) Not an Affiliate. Hsu is not an officer,
director or "affiliate" (as that term is defined in Rule 405 of the Act) of the
Company.
(f) Reliance on Representations and
Warranties. Hsu understands that the Securities are being offered and sold to
him in reliance on specific provisions of United States federal and state
securities laws and that the Company is relying upon the truth and
-2-
<PAGE>
accuracy of the representations, warranties, agreements, acknowledgments and
understandings of Hsu set forth in this Agreement in order to determine the
applicability of such provisions.
(g) No Registration. Hsu understands that
the sale of the Securities has not been registered under the Act, in reliance
upon an exemption therefrom by virtue of Section 4(2) and Regulation D
promulgated under the Act. Hsu understands that the Securities must be held
indefinitely and may not be offered, transferred, resold, pledged, hypothecated
or other wise disposed of until the sale or other transfer thereof is registered
under the Act, pursuant to the terms and conditions of the Registration Rights
Agreement or unless an exemption from such registration is available at that
time. Hsu is aware that he will be required to bear the financial risks of this
investment for an indefinite period of time unless transferred in accordance
with the above. Hsu covenants that he will not knowingly make any sale, transfer
or other disposition of the Securities or any interest therein in violation of
the Act, the Exchange Act of 1934, as amended, or the rules and regulations
promulgated under either of said Acts.
(h) Investment Intent. Hsu is acquiring the
Securities solely for his own account as principal and not with a view to the
distribution thereof to or for the benefit or account of any other person, in
whole or in part, and no other person has a direct or indirect beneficial
interest in such Securities. Hsu understands and agrees that he must bear the
economic risk of his investment in the Securities for an indefinite period of
time. Hsu will not take any short position in the Securities and not otherwise
engage in any hedging transactions such as option writing, equity swaps or other
types of derivative transactions with respect to the Securities.
(i) Additional Transfer Restrictions. Hsu
understands and agrees that, in addition to the restrictions set forth in this
Agreement, the following restrictions and limitations are applicable to his
purchase and any resales, pledges, hypothecations or other transfers of the
Securities:
(i) The following legend reflecting all
applicable restrictions will be placed on any certificate(s) or other
document(s) evidencing the Securities and Hsu must comply with the terms and
conditions set forth in such legends prior to any resales, pledges,
hypothecations or other transfers of the Securities:
"THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT") OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES HAVE
BEEN ACQUIRED FOR INVESTMENT PURPOSES
ONLY AND MAY NOT BE OFFERED FOR SALE,
SOLD, HYPOTHECATED, ASSIGNED, PLEDGED OR
OTHERWISE TRANSFERRED IN THE
-3-
<PAGE>
ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT COVERING THE SECURITIES UNDER
THE ACT OR APPLICABLE STATE SECURITIES
LAWS, OR AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT
REGISTRATION IS NOT REQUIRED UNDER THE
ACT OR APPLICABLE STATE SECURITIES LAWS.
(ii) Stop transfer instructions have
been or will be placed on any certificates or other documents evidencing the
Securities so as to restrict the resale, pledge, hypothecation or other transfer
thereof in accordance with the provisions hereof.
(j) Termination of Restrictions. The
restrictions described in Section 2 hereof upon the transferability of the
Securities shall cease and terminate as to any particular Securities (i) when,
in the opinion of Parker Chapin Flattau & Klimpl, LLP or other counsel
reasonably acceptable to the Company, such restrictions are no longer required
in order to assure compliance with the Act or (ii) when, in the opinion of
Parker Chapin Flattau & Klimpl, LLP or other counsel reasonably acceptable to
the Company, such Securities shall have been registered under the Act or
transferred in reliance upon the exemption afforded by Section 4(1) of the Act
by virtue of Rule 144.
(k) Indemnification. Hsu shall indemnify and
hold harmless the Company and each officer, director or control person of any
such entity, who is or may be a party or is or may be threatened to be made a
party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, by reason of or
arising from (i) any actual or alleged misrepresentation or misstatement of
facts or omission to represent or state facts made or alleged to have been made
by Hsu to the Company, (or its officers, directors, employees, agents or
representatives), or omitted or alleged to have been omitted by Hsu, concerning
Hsu, or Hsu's authority to invest or financial position in connection with the
offering or sale of the Securities, or (ii) any breach of warranty or failure to
comply with any covenant contained in this Agreement, including, without
limitation, any such misrepresentation, misstatement or omission, or breach of
any warranty or covenant, contained herein or any other document submitted by
Hsu, against losses, liabilities and expenses for which the Company, or its
officers, directors or control persons has not otherwise been reimbursed
(including attorneys' fees, judgments, fines and amounts paid in settlement in
matters settled in accordance with the provision of the following paragraph)
incurred by the Company, or such officer, director or control person in
connection with such action, suit or proceeding; provided, however, that Hsu
will not be liable in any such case for losses, claims, damages, liabilities or
expenses that a court of competent jurisdiction shall have found in a final
judgment to have arisen primarily from the gross negligence or willful
misconduct of the Company or the party claiming a right to indemnification.
-4-
<PAGE>
In case any proceeding shall be instituted involving any
person with respect to whom indemnity may be sought, such person (the
"Indemnified Party") shall promptly notify Hsu, and Hsu, upon the request of the
Indemnified Party, shall retain counsel reasonably satisfactory to the
Indemnified Party to represent the Indemnified Party and any others Hsu may
designate in such proceedings and shall pay as incurred the fees and expenses of
such counsel related to such proceeding. In any such proceeding, any Indemnified
Party shall have the right to retain its own counsel at its own expense, except
that Hsu shall pay as incurred the fees and expenses of counsel retained by the
Indemnified Party in the event that (i) Hsu and the Indemnified Party shall have
mutually agreed to the retention of such counsel or, (ii) the named parties to
any such proceeding (including any impleaded parties) include both Hsu and the
Indemnified Party and representation of both parties by the same counsel would
be inappropriate, in the reasonable opinion of the Indemnified Party, due to
actual or potential differing interests between them. Hsu shall not be liable
for any settlement of any proceeding effected without its written consent, but
if settled with such consent or if there be a final judgment for the plaintiff,
Hsu agrees to indemnify the Indemnified Party to the extent set forth in this
Agreement.
In the event a claim for indemnification as described herein
is determined to be unenforceable by a final judgment of a court of competent
jurisdiction, then Hsu shall contribute to the aggregate losses, claims, damages
or liabilities to which the Company or its officers, directors, agents,
employees or controlling persons may be subject in such amount as is appropriate
to reflect the relative benefits received by each of the undersigned and the
party seeking contribution on the one hand and the relative faults of Hsu and
the party seeking contribution on the other, as well as any relevant equitable
considerations.
The provisions of this Agreement relating to indemnification
and contribution shall survive termination of this Agreement and shall be
binding upon any successors or assigns of Hsu.
3. Representations and Warranties of the Company. The Company
acknowledges, represents, warrants and agrees as follows:
(a) Organization and Authorization. The
Company is a corporation duly organized, validly existing and in good standing
under the laws of the state of Florida and has all req uisite corporate power
and authority to own and operate its properties and assets and to carry on its
business as currently conducted. The Company is not in default or violation of
any material term or provision of its Articles of Incorporation or Bylaws nor
will the consummation of the transactions contemplated by this Agreement cause
any such default or violation. The Company has all requisite corporate power and
authority to enter into this Agreement, to sell the Securities hereunder and to
carry out and perform its obligations under the terms of this Agreement subject
to the above. This Agreement is a valid and binding obligation of the Company,
enforceable in accordance with its terms.
(b) Capitalization. The authorized capital
stock of the Company consists of 35,000,000 shares of Common Stock and 2,000,000
shares of Preferred Stock, par value $.02 per
-5-
<PAGE>
share. Upon issuance of the Securities pursuant to the terms of this Agreement
and payment therefor pursuant to the terms of an Asset Purchase Agreement
between Hsu and the Company, the Shares will be duly authorized, validly issued,
fully paid and nonassessable and the Warrant will be duly authorized and validly
issued. Upon issuance, the Shares will not be subject to any preemptive or other
preferential rights or similar statutory or contractual rights.
The Closing shall take place as soon as practicable after (i)
due execution by Hsu and acceptance by the Company of this Subscription
Agreement and (ii) the closings as contemplated by the Asset Purchase Agreement
and the Asset Purchase Agreement between Hsu and Conrex Pharmaceutical
Corporation.
4. Miscellaneous.
(a) Notices. All notices, demands or other
communications to be given or delivered under or by reason of the provisions of
this Agreement shall be in writing and shall be deemed to have been given (a)
when delivered personally to the recipient, (b) when sent to the recipient by
telecopy (receipt electronically confirmed by sender's telecopy machine) if
during normal business hours of the recipient, otherwise on the next Business
Day ("Business Day" means a day other than Saturday, Sunday or any day on which
banks located in the State of New York are authorized or obligated to close),
(c) one Business Day after the date when sent to the recipient by reputable
express courier service (charges prepaid) or (d) seven Business Days after the
date when mailed to the recipient by certified or registered mail, return
receipt requested and postage prepaid. Such notices, demands and other
communications will be sent to Hsu and to the Company at the addresses indicated
below.
If to Hsu, to:
Yungtai Hsu
Facsimile No.:
With a copy (which shall not constitute notice) to:
Lagerlof, Senecal, Bradley, Gosney & Kruse, LLP
301 North Lake Avenue, 10th Floor
Pasadena, CA 91101
Attention: Timothy J. Gosney
Facsimile No.: (626) 793-5900
-6-
<PAGE>
If to the Company, to:
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
Attention: James R. Murphy
Facsimile No.: (813) 282-8941
With a copy (which shall not constitute notice) to:
Parker Chapin Flattau & Klimpl, LLP
1211 Avenue of the Americas
New York, New York 10036
Attention: Mark S. Hirsch
Jordan A. Horvath
Facsimile No.: (212) 704-6288
(b) Assignment; Benefit. This Agreement may
not be assigned by Hsu without the prior written consent of the Company and any
assignment without such consent shall be void. This Agreement may be assigned by
the Company to any person or entity which purchases all or substantially all of
the stock or assets of the Company or is the successor to the Company by merger
or consolidation. This Agreement shall be binding upon and inure to the benefit
of the respective successors and permitted assigns of the Company and of Hsu.
(c) Severability. The invalidity or
unenforceability of any provisions of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, each of
which shall remain in full force and effect.
(d) Amendments. This Agreement may be
amended, supplemented or modified, and any provision hereof may be waived, only
pursuant to a written instrument making specific reference to this Agreement
signed by each of the parties hereto.
(e) Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.
(f) Governing Law. This Agreement shall be
governed by and construed in accordance with the laws of the State of New York
applicable to a contract executed and performed in such State without giving
effect to the conflicts of laws principles thereof, except that if it is
necessary in any other jurisdiction to have the law of such other jurisdiction
govern this
-7-
<PAGE>
Agreement in order for this Agreement to be effective in any respect, then the
laws of such other jurisdiction shall govern this Agreement to such extent.
(g) Arbitration of Disputes
(i) If any controversy or dispute arises
under, out of or in relation to any of the provisions hereof, such controversy
or dispute shall be submitted for arbitration in New York, New York before a
panel of three arbitrators, one of which shall be selected by the party
initiating such arbitration, one of which shall be selected by the other party
and the third of which (the "Third Arbitrator") shall be selected by the two
arbitrators so selected; provided, however, that in the event that such other
arbitrators shall not agree on the selection of the Third Arbitrator, the Third
Arbitrator shall be selected by the American Arbitration Association located in
New York, New York. Any dispute or controversy submitted to arbitration in
accordance with the provisions of this Section shall be determined by such
arbitrators in accordance with the Commercial Arbitration Rules of the American
Arbitration Association then existing.
(ii) The arbitrators may award any
relief which they shall deem proper in the circumstances, without regard to the
relief which would otherwise be available to any party in a court of law or
equity including, without limitation, an award of money damages, specific
performance, injunctive relief and/or declaratory relief, however, such an award
may not include punitive damages. The award and findings of the arbitrators
shall be conclusive and binding upon all of the parties hereto, whether or not
all parties hereto participate in the arbitration proceeding, and judgment upon
the award may be entered in any court of competent jurisdiction upon the
application of any party. The parties hereby agree that such courts of competent
jurisdiction shall include, but not be limited to, the courts located in any
jurisdiction in which the party against whom such judgment is being enforced
maintains any assets.
(iii) The prevailing party in the
arbitration proceeding shall be entitled to recover from the other party its
reasonable attorneys' fees, costs and expenses incurred in the proceeding and in
any subsequent action to enforce or collect upon the decision rendered in the
arbitration proceeding.
(iv) Notwithstanding the foregoing, the
parties reserve the right to seek and obtain injunctive relief, whether in the
form of a temporary restraining order, preliminary injunction, injunction to
enforce an arbitration award, or other order of similar import, from the federal
and state courts located in New York, New York prior to, during, or after
commencement or prosecution or arbitration proceedings of the final decision and
award of the arbitrators; provided, however, that such preliminary injunctive
relief shall be subject to final arbitral decisions.
(v) Each party hereby consents and
agrees that the federal and state courts located in New York, New York each
shall have exclusive personal jurisdiction and proper venue with respect to any
such action seeking injunctive or similar relief
-8-
<PAGE>
hereunder. In any dispute between the parties, neither party will raise, and
each party hereby expressly waives, any objection or defense to any such court
as an inconvenient forum. Each party hereby waives personal service of any
summons, complaint or other process, which may be delivered by any of the means
permitted for notices under Section 6(a) hereof.
(h) Entire Agreement. This Agreement
constitutes the entire agreement between Hsu and the Company with respect to the
subject matter hereof.
/s/ Yungtai Hsu
-------------------------------------
Yungtai Hsu, in his personal capacity
ACCEPTED AND AGREED:
BENTLEY PHARMACEUTICALS, INC.
By: /s/ James R. Murphy
------------------------------------
James R. Murphy, Chairman, President
and Chief Executive Officer
-9-
REGISTRATION RIGHTS AGREEMENT
-----------------------------
THIS REGISTRATION RIGHTS AGREEMENT, is made and entered into
as of February 11, 1999 between BENTLEY PHARMACEUTICALS, INC., a Florida
corporation (the "Company") and Yungtai Hsu ("Hsu").
WHEREAS, upon the terms and subject to the conditions of an
Asset Purchase Agreement, dated February 1, 1999, effective as of December 31,
1998 (the "Asset Purchase Agreement"), between the Company and Hsu, in which Hsu
agreed to sell certain of his assets to the Company, Hsu has agreed to accept
225,807 shares (the "Shares") of common stock, $0.02 par value per share (the
"Common Stock") of the Company as part of the Purchase Price (as defined in the
Asset Purchase Agreement);
WHEREAS, to induce Hsu to accept the Shares as part of the
Purchase Price, the Company has agreed to provide certain registration rights
under the Securities Act of 1933, as amended, and the rules and regulations
thereunder, or any similar successor statute (collectively, the "Act"), with
respect to the Shares;
WHEREAS, as of the date hereof, Hsu and the Company entered
into a Subscription Agreement with respect to the Shares (the "Subscription
Agreement");
NOW, THEREFORE, in consideration of the premises and the
mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and Hsu
hereby agree as follows:
1. Definitions.
(a) As used in this Agreement, the following terms shall have
the following meanings:
(i) "Register," "Registered," and "Registration" refer to a
registration effected by preparing and filing a Registration Statement in
compliance with the Act and the declaration or ordering of effectiveness of such
Registration Statement by the United States Securities and Exchange Commission
(the "SEC").
(ii) "Registrable Securities" means the Shares.
(iii) "Registration Statement" means a registration statement
of the Company under the Act, including any amendments or supplements thereto
and prospectuses contained therein.
<PAGE>
(iv) "Stockholder" means Hsu and any permitted transferee or
assignee who agrees to become bound by the provisions of this Agreement in
accordance with Section 9 hereof.
(b) Capitalized terms used herein and not otherwise defined
herein shall have the respective meanings set forth in the Asset Purchase
Agreement.
2. Restrictions on Transfer.
(a) The Stockholder acknowledges and understands that prior to
the registration of the Shares as provided herein, the Shares are "restricted
securities" as defined in Rule 144 promulgated under the Act ("Rule 144"). The
Stockholder understands that the Shares may not be offered, transferred, resold,
pledged, hypothecated or otherwise disposed of in the absence of (i) an opinion
of Parker Chapin Flattau & Klimpl, LLP or other counsel reasonably acceptable to
the Company that such transfer may be made without registration under the Act or
(ii) an opinion of Parker Chapin Flattau & Klimpl, LLP or other counsel
reasonably acceptable to the Company that the Shares have been Registered.
(b) The Stockholder acknowledges that the Company has issued
the Shares to the Stockholder pursuant to an exemption from registration under
the Act. Stockholder represents that (i) he has acquired the Shares for
investment and without any view toward distribution of any of Registrable
Securities to any other person, (ii) he will not sell or otherwise dispose of
the Shares except in compliance with the registration requirements or exemption
provisions under the Act and (iii) before any sale or other disposition of any
of the Shares other than in a sale registered under the Act or pursuant to Rule
144 or 144A (or any similar provisions then in force) under the Act (unless the
Company shall have been advised by counsel that the sale does not meet the
requirements of Rule 144 or Rule 144A, as the case may be, for such sale), he
will deliver to the Company an opinion of counsel, in form and substance
reasonably satisfactory to the Company, to the effect that such registration is
unnecessary.
(c) Each instrument or certificate evidencing or representing
the Shares, and any certificate issued in exchange therefor or transfer thereof,
shall bear legends substantially in the following form:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT") OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE
OFFERED FOR SALE, SOLD, HYPOTHECATED, ASSIGNED, PLEDGED OR
OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT COVERING THE SECURITIES UNDER THE ACT
OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT
-2-
<PAGE>
REGISTRATION IS NOT REQUIRED UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS.
3. Registration.
(a) If at any time or from time to time following the date
hereof, the Company shall determine to register any distribution of its
securities with the SEC, either for its own account or the account of a security
holder or holders, in a registration statement covering the sale of shares of
Common Stock to the general public pursuant to a public offering in compliance
with the Act (except with respect to any registration filed on Form S-4 or such
other form which does not include substantially the same information as would be
included in a registration statement covering the sale of shares of Common Stock
to the general public), the Company will: (i) give to Stockholder written notice
thereof at least 30 days before the initial filing of such registration
statement; and (ii) include in such registration (and any related qualification
under blue sky laws) and in any underwriting involved therein, all the Shares,
specified in a written request, made within 30 days after receipt of such
written notice from the Company, by the Stockholder, except as set forth in
subparagraphs (b) or below. Notwithstanding the foregoing, the Stockholder shall
not have registration rights with respect to a particular registration statement
in the event that any investor or lender for whom the registration statement is
filed objects to the inclusion of other shares of Common Stock, including the
Shares, in such registration statement.
(b) If the distribution is to be underwritten, the right of
the Stockholder to registration pursuant to this Section shall be conditioned
upon Stockholder's participation in the underwriting and the inclusion of the
Shares and securities underlying the Shares, as the case may be, in the
underwriting to the extent provided herein. Notwithstanding any other provision
of this Section, if the underwriter determines that marketing factors require a
limitation of the number of shares to be underwritten, and such determination is
made by such underwriter in writing, then the underwriter may limit the number
of the Stockholder's Shares to be included in the registration and underwriting,
or may exclude the Shares from such underwriting.
4. Obligations of the Company. In connection with a
registration of the Registrable Securities under Section 3 hereof, the Company
shall do each of the following:
(a) Prepare and file with the SEC, a Registration Statement
with respect to the Registrable Securities, and thereafter use its best efforts
to cause each Registration Statement relating to the Registrable Securities to
become effective on or before 120 days from the filing of such Registration
Statement with the SEC, and keep the Registration Statement effective at all
times until the earliest (the "Registration Period") of (i) the date that is
three years after the Closing Date; (ii) the date when the Stockholder may sell
all Registrable Securities under Rule 144 or (iii) the date the Stockholder no
longer owns any of the Registrable Securities, which Registration Statement
shall not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading;
-3-
<PAGE>
(b) Prepare and file with the SEC such amendments (including
post-effective amendments) and supplements to the Registration Statement and the
prospectus used in connection with the Registration Statement as may be
necessary to keep the Registration Statement effective at all times during the
Registration Period, and, during the Registration Period, comply with the
provisions of the Act with respect to the disposition of all Registrable
Securities of the Company covered by the Registration Statement until such time
as all of such Registrable Securities have been disposed of in accordance with
the intended methods of disposition by the seller or sellers thereof as set
forth in the Registration Statement;
(c) The Company shall permit a single firm of counsel
designated by the Stockholder to review the Registration Statement a reasonable
period of time prior to the Company's filing of the Registration Statement with
the SEC;
(d) Furnish to the Stockholder (i) promptly after the
Registration Statement is prepared and publicly distributed, filed with the SEC,
or received by the Company, one copy of the Registration Statement, each
prospectus, and each amendment or supplement thereto, and (ii) such number of
copies of a prospectus, and all amendments and supplements thereto and such
other documents, as the Stockholder may reasonably request in order to
facilitate the disposition of the Registrable Securities owned by the
Stockholder;
(e) As promptly as practicable after becoming aware of such
event, the Company shall notify the Stockholder of (i) the issuance by the SEC
of a stop order suspending the effectiveness of the Registration Statement, (ii)
the happening of any event of which the Company has knowledge as a result of
which the prospectus included in the Registration Statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading, or
(iii) the occurrence or existence of any pending corporate development that, in
the reasonable discretion of the Company, makes it appropriate to suspend the
availability of the Registration Statement, and use its best efforts promptly to
prepare a supplement or amendment to the Registration Statement to correct such
untrue statement or omission, and deliver such number of copies of such
supplement or amendment to the Stockholder as he may reasonably request;
provided that, for not more than twenty days (or a total of not more than forty
days in any twelve month period, the Company may delay the disclosure of
material non-public information concerning the Company (as well as prospectus or
Registration Statement updating) the disclosure of which at the time is not, in
the good faith opinion of the Company, the best interests of the Company and in
the opinion of counsel to the Company (an "Allowed Delay"); provided, further,
that the Company shall promptly (i) notify the Stockholder in writing of the
existence of material non-public information giving rise to an Allowed Delay and
(ii) advise the Stockholder in writing to cease all sales under the Registration
Statement until the end of the Allowed Delay. Upon expiration of the Allowed
Delay, the Company shall again be bound by the first sentence of this Section
4(e) with respect to the information giving rise thereto;
(f) As promptly as practicable after becoming aware of such
event, notify the Stockholder who holds Registrable Securities being sold (or,
in the event of an underwritten offering,
-4-
<PAGE>
the managing underwriters) of the issuance by the SEC of any notice declaring
the effectiveness of the Registration Statement or any stop order or other
suspension of the effectiveness of the Registration Statement at the earliest
possible time; and
(g) Take all other reasonable actions necessary to expedite
and facilitate disposition by the Stockholder of the Registrable Securities
pursuant to the Registration Statement.
5. Obligations of the Stockholder. In connection with the
registration of the Registrable Securities, the Stockholder shall have the
following obligations:
(a) It shall be a condition precedent to the obligations of
the Company to complete the registration pursuant to this Agreement with respect
to the Registrable Securities of the Stockholder that the Stockholder shall
furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of the Registrable
Securities held by it, as shall be reasonably required to effect the
registration of such Registrable Securities and shall execute such documents in
connection with such registration as the Company may reasonably request. At
least five days prior to the first anticipated filing date of the Registration
Statement, the Company shall notify the Stockholder of the information the
Company requires from the Stockholder (the "Requested Information") if the
Stockholder elects to have any of the Stockholder's Registrable Securities
included in the Registration Statement. If at least three Business Days (as
defined below) prior to the filing date the Company has not received the
Requested Information from the Stockholder, then the Company may file the
Registration Statement without including Registrable Securities of the
Stockholder;
(b) The Stockholder by acceptance of the Registrable
Securities agrees to cooperate with the Company as reasonably requested by the
Company in connection with the preparation and filing of the Registration
Statement hereunder, unless the Stockholder has notified the Company in writing
of the Stockholder's election to exclude all of its Registrable Securities from
the Registration Statement; and
(c) The Stockholder agrees that, upon receipt of any notice
from the Company of the happening of any event of the kind described in Section
4(e) or 4(f), above, the Stockholder will immediately discontinue disposition of
Registrable Securities pursuant to the Registration Statement covering such
Registrable Securities until the Stockholder's receipt of the copies of the
supplemented or amended prospectus contemplated by Section 4(e) or 4(f) and, if
so directed by the Company, the Stockholder shall deliver to the Company (at the
expense of the Company) or destroy (and deliver to the Company a certificate of
destruction) all copies in the Stockholder's possession, of the prospectus
covering such Registrable Securities current at the time of receipt of such
notice.
6. Expenses of Registration.
(a) All reasonable expenses, other than as set forth in
Section 6(b) hereof, filings or qualifications pursuant to Section 4, including,
without limitation, all registration, listing, and
-5-
<PAGE>
qualifications fees, printers and accounting fees, the fees and disbursements of
counsel for the Company, shall be borne by the Company.
(b) All underwriting discounts and commissions incurred in
connection with registrations shall be paid by the Stockholder.
7. Indemnification. Hsu shall indemnify and hold harmless the
Company and each officer, director or control person of any such entity, who is
or may be a party or is or may be threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of or arising from (i) any
actual or alleged misrepresentation or misstatement of facts or omission to
represent or state facts made or alleged to have been made by Hsu to the
Company, (or its officers, directors, employees, agents or representatives), or
omitted or alleged to have been omitted by Hsu, concerning Hsu, or Hsu's
authority to invest or financial position in connection with the offering or
sale of the Shares, or (ii) any breach of warranty or failure to comply with any
covenant contained in this Agreement, including, without limitation, any such
misrepresentation, misstatement or omission, or breach of any warranty or
covenant, contained herein or any other document submitted by Hsu, against
losses, liabilities and expenses for which the Company, or its officers,
directors or control persons has not otherwise been reimbursed (including
attorneys' fees, judgments, fines and amounts paid in settlement in matters
settled in accordance with the provision of the following paragraph) incurred by
the Company, or such officer, director or control person in connection with such
action, suit or proceeding; provided, however, that Hsu will not be liable in
any such case for losses, claims, damages, liabilities or expenses that a court
of competent jurisdiction shall have found in a final judgment to have arisen
primarily from the gross negligence or willful misconduct of the Company or the
party claiming a right to indemnification.
In case any proceeding shall be instituted involving any
person with respect to whom indemnity may be sought, such person (the
"Indemnified Party") shall promptly notify Hsu, and Hsu, upon the request of the
Indemnified Party, shall retain counsel reasonably satisfactory to the
Indemnified Party to represent the Indemnified Party and any others Hsu may
designate in such proceedings and shall pay as incurred the fees and expenses of
such counsel related to such proceeding. In any such proceeding, any Indemnified
Party shall have the right to retain its own counsel at its own expense, except
that Hsu shall pay as incurred the fees and expenses of counsel retained by the
Indemnified Party in the event that (i) Hsu and the Indemnified Party shall have
mutually agreed to the retention of such counsel or, (ii) the named parties to
any such proceeding (including any impleaded parties) include both Hsu and the
Indemnified Party and representation of both parties by the same counsel would
be inappropriate, in the reasonable opinion of the Indemnified Party, due to
actual or potential differing interests between them. Hsu shall not be liable
for any settlement of any proceeding effected without its written consent, but
if settled with such consent or if there be a final judgment for the plaintiff,
Hsu agrees to indemnify the Indemnified Party to the extent set forth in this
Agreement.
In the event a claim for indemnification as described herein
is determined to be unenforceable by a final judgment of a court of competent
jurisdiction, then Hsu shall contribute to
-6-
<PAGE>
the aggregate losses, claims, damages or liabilities to which the Company or its
officers, directors, agents, employees or controlling persons may be subject in
such amount as is appropriate to reflect the relative benefits received by each
of the undersigned and the party seeking contribution on the one hand and the
relative faults of Hsu and the party seeking contribution on the other, as well
as any relevant equitable considerations.
The provisions of this Agreement relating to indemnification
and contribution shall survive termination of this Agreement and shall be
binding upon any successors or assigns of Hsu.
8. Termination of Registration Rights. The rights granted
pursuant to this Agreement shall terminate as to the Stockholder upon the
occurrence of any of the following:
(a) all of the Registrable Securities have been registered; or
(b) all of the Registrable Securities may be sold without such
registration pursuant to Rule 144.
9. Miscellaneous.
(a) A person or entity is deemed to be a holder of Registrable
Securities whenever such person or entity owns of record such Registrable
Securities. If the Company receives conflicting instructions, notices or
elections from two or more persons or entities with respect to the same
Registrable Securities, the Company shall act upon the basis of instructions,
notice or election received from the registered owner of such Registrable
Securities.
(b) Notices. All notices, demands or other communications to
be given or delivered under or by reason of the provisions of this Agreement
shall be in writing and shall be deemed to have been given (a) when delivered
personally to the recipient, (b) when sent to the recipient by telecopy (receipt
electronically confirmed by sender's telecopy machine) if during normal business
hours of the recipient, otherwise on the next Business Day ("Business Day" means
a day other than Saturday, Sunday or any day on which banks located in the State
of New York are authorized or obligated to close), (c) one Business Day after
the date when sent to the recipient by reputable express courier service
(charges prepaid) or (d) seven Business Days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage
prepaid. Such notices, demands and other communications will be sent to Hsu and
to the Company at the addresses indicated below.
If to Hsu, to:
Yungtai Hsu
Facsimile No.:
-7-
<PAGE>
With a copy (which shall not constitute notice) to:
Lagerlof, Senecal, Bradley, Gosney & Kruse, LLP
301 North Lake Avenue, 10th Floor
Pasadena, CA 91101
Attention: Timothy J. Gosney
Facsimile No.: (626) 793-5900
If to the Company, to:
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
Attention: James R. Murphy
Facsimile No.: (813) 282-8941
With a copy (which shall not constitute notice) to:
Parker Chapin Flattau & Klimpl, LLP
1211 Avenue of the Americas
New York, New York 10036
Attention: Mark S. Hirsch
Jordan A. Horvath
Facsimile No.: (212) 704-6288
(c) Assignment; Benefit. This Agreement may not be assigned by
Hsu without the prior written consent of the Company and any assignment without
such consent shall be void. This Agreement may be assigned by the Company to any
person or entity which purchases all or substantially all of the stock or assets
of the Company or is the successor to the Company by merger or consolidation.
This Agreement shall be binding upon and inure to the benefit of the respective
successors and permitted assigns of the Company and of Hsu.
(d) Severability. The invalidity or unenforceability of any
provisions of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, each of which shall remain in full force
and effect.
(e) Amendments. This Agreement may be amended, supplemented or
modified, and any provision hereof may be waived, only pursuant to a written
instrument making specific reference to this Agreement signed by each of the
parties hereto.
(f) Counterparts. This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
-8-
<PAGE>
(g) Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to a
contract executed and performed in such State without giving effect to the
conflicts of laws principles thereof, except that if it is necessary in any
other jurisdiction to have the law of such other jurisdiction govern this
Agreement in order for this Agreement to be effective in any respect, then the
laws of such other jurisdiction shall govern this Agreement to such extent.
(h) Arbitration of Disputes
(i) If any controversy or dispute arises
under, out of or in relation to any of the provisions hereof, such controversy
or dispute shall be submitted for arbitration in New York, New York before a
panel of three arbitrators, one of which shall be selected by the party
initiating such arbitration, one of which shall be selected by the other party
and the third of which (the "Third Arbitrator") shall be selected by the two
arbitrators so selected; provided, however, that in the event that such other
arbitrators shall not agree on the selection of the Third Arbitrator, the Third
Arbitrator shall be selected by the American Arbitration Association located in
New York, New York. Any dispute or controversy submitted to arbitration in
accordance with the provisions of this Section shall be determined by such
arbitrators in accordance with the Commercial Arbitration Rules of the American
Arbitration Association then existing.
(ii) The arbitrators may award any relief
which they shall deem proper in the circumstances, without regard to the relief
which would otherwise be available to any party in a court of law or equity
including, without limitation, an award of money damages, specific performance,
injunctive relief and/or declaratory relief, however, such an award may not
include punitive damages. The award and findings of the arbitrators shall be
conclusive and binding upon all of the parties hereto, whether or not all
parties hereto participate in the arbitration proceeding, and judgment upon the
award may be entered in any court of competent jurisdiction upon the application
of any party. The parties hereby agree that such courts of competent
jurisdiction shall include, but not be limited to, the courts located in any
jurisdiction in which the party against whom such judgment is being enforced
maintains any assets.
(iii) The prevailing party in the
arbitration proceeding shall be entitled to recover from the other party its
reasonable attorneys' fees, costs and expenses incurred in the proceeding and in
any subsequent action to enforce or collect upon the decision rendered in the
arbitration proceeding.
(iv) Notwithstanding the foregoing, the
parties reserve the right to seek and obtain injunctive relief, whether in the
form of a temporary restraining order, preliminary injunction, injunction to
enforce an arbitration award, or other order of similar import, from the federal
and state courts located in New York, New York prior to, during, or after
commencement or prosecution or arbitration proceedings of the final decision and
award of the arbitrators; provided, however, that such preliminary injunctive
relief shall be subject to final arbitral decisions.
-9-
<PAGE>
(v) Each party hereby consents and agrees
that the federal and state courts located in New York, New York each shall have
exclusive personal jurisdiction and proper venue with respect to any such action
seeking injunctive or similar relief hereunder. In any dispute between the
parties, neither party will raise, and each party hereby expressly waives, any
objection or defense to any such court as an inconvenient forum. Each party
hereby waives personal service of any summons, complaint or other process, which
may be delivered by any of the means permitted for notices under Section 9(b)
hereof
IN WITNESS WHEREOF, the parties have executed and delivered
this Agreement as of the day and year first written above.
BENTLEY PHARMACEUTICALS, INC.
By: /s/ James R. Murphy
------------------------------------
James R. Murphy, Chairman, President
and Chief Executive Officer
/s/ Yungtai Hsu
-------------------------------------
Yungtai Hsu, in his personal capacity
-10-
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED AND MAY
NOT BE TRANSFERRED UNLESS (A) THE STOCKHOLDER WISHING TO TRANSFER SUCH
SECURITIES PROVIDES AN OPINION OF COUNSEL REASONABLY CONCURRED IN BY COUNSEL FOR
BENTLEY PHARMACEUTICALS, INC. (THE "COMPANY") STATING THAT THE PROPOSED TRANSFER
OF THE COMPANY'S SECURITIES IS EXEMPT FROM OR NOT SUBJECT TO THE REGISTRATION
PROVISIONS OF ALL APPLICABLE FEDERAL AND STATE LAWS; OR (B) SAID SECURITIES HAVE
BEEN REGISTERED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED.
February 11, 1999
BENTLEY PHARMACEUTICALS, INC.
The Transferability of this Warrant is
Restricted as Provided in Article 3
In partial consideration of the purchase of certain assets
under an Asset Purchase Agreement dated February 1, 1999 effective as of
December 31, 1998 between Bentley Pharmaceuticals, Inc. and Yungtai Hsu and
other good and valuable consideration, the receipt of which is hereby
acknowledged by BENTLEY PHARMACEUTICALS, INC., Two Urban Centre, Suite 400, 4890
West Kennedy Boulevard, Tampa, Florida 33609, a Florida corporation (the
"Company"), YUNGTAI HSU (the "Holder") is hereby granted the right to purchase,
at the initial exercise price of $ 1.50 per share, at any time until 5:00 P.M.,
New York time, on December 31, 2008, Four Hundred Fifty Thousand (450,000)
shares of the Company's common stock, $.02 par value per share (the "Shares").
This Warrant initially is exercisable at a price of $1.50 per
Share payable in cash or by certified or official bank check in New York
Clearing House funds, subject to adjustment as provided in Article 6 hereof.
Upon surrender of this Warrant, with the annexed Subscription Form duly
executed, together with payment of the Purchase Price (as hereinafter defined)
for the Shares purchased, at the offices of the Company, the registered holder
of this Warrant (the "Holder") shall be entitled to receive a certificate or
certificates for the Shares so purchased.
THIS WARRANT MAY NOT BE EXERCISED AND THE SHARES MAY NOT BE
ISSUED UNTIL A LISTING APPLICATION RELATING TO THE SHARES HAS BEEN APPROVED BY
ALL SECURITIES EXCHANGES ON WHICH THE SHARES OF THE COMPANY'S COMMON STOCK MAY
THEN BE LISTED AND/OR QUOTED.
<PAGE>
1. Exercise of Warrant.
The purchase rights represented by this Warrant are
exercisable at the option of the Holder hereof, in whole or in part (but not as
to fractional Shares underlying this Warrant), during any period in which this
Warrant may be exercised as set forth above. In the case of the purchase of less
than all the Shares purchasable under this Warrant, the Company shall cancel
this Warrant upon the surrender hereof and shall execute and deliver a new
Warrant of like tenor for the balance of the Shares purchasable hereunder.
2. Issuance of Certificates.
Upon the exercise of this Warrant, the issuance of
certificates for Shares underlying this Warrant shall be made forthwith (and in
any event within five business days thereafter) without charge to the Holder
hereof including, without limitation, any tax which may be payable in respect of
the issuance thereof, and such certificates shall (subject to the provisions of
Articles 3 hereof) be issued in the name of, or in such names as may be directed
by, the Holder hereof; provided, however, that the Company shall not be required
to pay any tax which may be payable in respect of any transfer involved in the
issuance and delivery of any such certificates in a name other than that of the
Holder and the Company shall not be required to issue or deliver such
certificates unless or until the person or persons requesting the issuance
thereof shall have paid to the Company the amount of such tax or shall have
established to the satisfaction of the Company that such tax has been paid. The
certificates representing the Shares underlying this Warrant shall be executed
on behalf of the Company by the manual or facsimile signature of one of the
present or any future Chairman or President of the Company and any present or
future Vice President or Secretary of the Company.
3. Restriction on Transfer of Warrant.
The Holder of this Warrant, by its acceptance hereof,
covenants and agrees that this Warrant is being acquired as an investment and
not with a view to the distribution hereof, and that it may not be exercised,
sold, transferred, assigned, hypothecated or otherwise disposed of, in whole or
in part except as provided in Section 13 below or unless in the opinion of
counsel concurred in by the Company's counsel such transfer is in compliance
with all applicable securities laws.
4. Price.
(a) Initial and Adjusted Purchase Price. The initial purchase price
shall be $1.50 per Share. The adjusted purchase price shall be the price which
shall result from time to time from any and all adjustments of the initial
purchase price in accordance with the provisions of Article 5 hereof.
(b) Purchase Price. The term "Purchase Price" herein shall mean the
initial purchase price or the adjusted purchase price, depending upon the
context.
-2-
<PAGE>
5. Adjustments of Purchase Price and Number of Shares.
(a) Subdivision and Combination. In case the Company shall at any time
subdivide or combine the outstanding Shares, the Purchase Price shall forthwith
be proportionately decreased in the case of subdivision or increased in the case
of combination.
(b) Adjustment in Number of Shares. Upon each adjustment of the
Purchase Price pursuant to the provisions of this Article 5, the number of
Shares issuable upon the exercise of this Warrant shall be adjusted to the
nearest full Share by multiplying a number equal to the Purchase Price in effect
immediately prior to such adjustment by the number of Shares issuable upon
exercise of this Warrant immediately prior to such adjustment and dividing the
product so obtained by the adjusted Purchase Price.
(c) Reclassification, Consolidation, Merger, etc. In case of any
reclassification or change of the outstanding Shares (other than a change in par
value to no par value, or from no par value to par value, or as a result of a
subdivision or combination), or in the case of any consolidation of the Company
with, or merger of the Company into, another corporation (other than a
consolidation or merger in which the Company is the surviving corporation and
which does not result in any reclassification or change of the outstanding
Shares, except a change as a result of a subdivision or combination of such
shares or a change in par value, as aforesaid), or in the case of a sale or
conveyance to another corporation of the property of the Company as an entirety,
the Holder of this Warrant shall thereafter have the right to purchase upon the
exercise of this Warrant the kind and number of shares of stock and other
securities and property receivable upon such reclassification, change,
consolidation, merger, sale or conveyance as if the Holder were the owner of the
Shares underlying this Warrant immediately prior to any such events at the
Purchase Price in effect immediately prior to the record date for such
reclassification, change, consolidation, merger, sale or conveyance as if such
Holder had exercised this Warrant.
6. Exchange and Replacement of Warrant.
This Warrant is exchangeable without expense, upon the
surrender hereof by the registered Holder at the principal executive office of
the Company for a new Warrant of like tenor and date representing in the
aggregate the right to purchase the same number of Shares as are purchasable
hereunder in such denominations as shall be designated by the Holder hereof at
the time of such surrender.
Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this
Warrant, and, in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it, and reimbursement to the Company of all
reasonable expenses incidental thereto, and upon surrender and cancellation of
this Warrant, if mutilated, the Company will make and deliver a new Warrant of
like tenor, in lieu of this Warrant.
-3-
<PAGE>
7. Elimination of Fractional Interests.
The Company shall not be required to issue certificates
representing fractions of Shares on the exercise of this Warrant, nor shall it
be required to issue scrip or pay cash in lieu of fractional interests, it being
the intent of the parties that all fractional interests shall be eliminated
pursuant to Section 5(b).
8. Reservation and Listing of Securities.
The Company shall at all times reserve and keep available out
of its authorized Shares, solely for the purpose of issuance upon the exercise
of this Warrant, such number of Shares as shall be issuable upon the exercise
hereof and thereof. The Company covenants and agrees that, upon exercise of this
Warrant and payment of the Purchase Price therefor, all Shares issuable upon
such exercise shall be duly and validly issued, fully paid and non-assessable.
As long as this Warrant shall be outstanding, the Company shall use its
reasonable best efforts to cause all Shares issuable upon the exercise of this
Warrant to be listed (subject to official notice of issuance) on all securities
exchanges on which the Shares of the Company's Common Stock may then be listed
and/or quoted.
9. Repurchase at Option of Holder.
(a) If on December 31, 2000 (the "Repurchase Date"), the Market Price
(as defined herein) does not equal or exceed 150 % of the Purchase Price, the
Holder shall have the right (the "Put Right") to require the Company to purchase
all or a portion of this Warrant relating to that number of Shares which the
Holder is relinquishing its right to purchase (the "Relinquished Shares"), for a
price equal to $0.50 (fifty cents) multiplied by the number of Relinquished
Shares. The Put Right must be exercised by a written notice from the Holder to
the Company within ten (10) days of the Repurchase Date and the Company shall
pay to the Holder the amounts owing hereunder within ten (10) days of receipt of
such notice, this Warrant and such other documentation as the Company may
reasonably require.
(b) The Put Right shall not be exercisable by the Holder if, during any
twenty consecutive trading days between the issuance of this Warrant and the
Repurchase Date, the Market Price shall be equal to or greater than $3.00 per
share.
(c) The "Market Price" per share on any date shall be deemed to be the
daily closing price per share. The closing price per Share for each day shall be
the last reported sales price regular way or, in case no such sale takes place
on such day, the average of the closing bid and asked prices regular way, in
either case on the American Stock Exchange, or, if the Common Stock is not
listed or admitted to trading on the American Stock Exchange, on the principal
national securities exchange on which the Common Stock is listed or admitted to
trading, or if it is not listed or admitted to trading on any national
securities exchange or no such quotations are available, the last reported sale
price, or if not so reported, the average of the closing bid and asked prices as
furnished by any New York Stock Exchange member firm selected from time to time
by the Company for that purpose, or,
-4-
<PAGE>
if no such quotations are available, the fair market value as determined in good
faith in the exercise of their reasonable business judgment by the Board of
Directors of the Company.
10. Repurchase at Option of the Company
This Warrant may be redeemed at the option of the Company at
any time, at a redemption price of $0.05 per Share for which the Warrant is
exercisable, provided the Market Price for the Shares for any twenty (20)
consecutive trading days after the issuance of this Warrant shall be equal to or
greater than $5.00 per share. Notice of redemption shall be given in writing to
the Holder not less than ten days before the date fixed for redemption. On and
after the date fixed for redemption, the Holder shall have no rights with
respect to this Warrant except to receive the $0.05 per Share upon surrender of
the Warrant.
11. Notices.
All notices, demands or other communications to be given or
delivered under or by reason of the provisions of this Warrant shall be in
writing and shall be deemed to have been given (a) when delivered personally to
the recipient, (b) when sent to the recipient by telecopy (receipt
electronically confirmed by sender's telecopy machine) if during normal business
hours of the recipient, otherwise on the next Business Day, (c) one Business Day
after the date when sent to the recipient by reputable express courier service
(charges prepaid) or (d) seven Business Days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage
prepaid. Such notices, demands and other communications will be sent:
(a) if to the registered Holder of this Warrant, to the
address of such Holder as shown on the books of the Company; or
(b) if to the Company, to the address set forth on the first
page of this Warrant or to such other address as the Company may
designate by notice to the Holder.
12. Amendments.
The terms, provisions and conditions of this Warrant may not
be changed, modified or amended in any manner except by an instrument in writing
duly executed by both parties hereto.
13. Binding Effect; Assignment.
(a) This Warrant is not assignable or transferable without the
written consent of the Company, except by operation of law or as provided in (b)
below.
(b) This Warrant shall not be transferable by Holder other
than to a "Permitted Transferee" (as defined below); provided, that any
Permitted Transferee shall be absolutely prohibited from transferring all or any
portion of this Warrant other than to Holder or another
-5-
<PAGE>
Permitted Transferee of Holder; and provided further, that if Holder dies or
becomes incapacitated, this Warrant may be exercised by Holder's estate, legal
representative or beneficiary, as the case may be, subject to all other terms
and conditions contained in this Warrant.
(c) For purposes of this Warrant, Permitted Transferees shall
include only the members of the Holder's "immediate family" (which shall be
limited to Holder's spouse, children, and parents), and to trusts for such
person's own benefit and/or for the benefit of members of Holder's immediate
family; provided, that such Permitted Transferees must agree in writing to be
bound by all of the terms of this Warrant to the same extent as Holder
hereunder, in form acceptable to counsel to the Company, including but not
limited to restrictions on the exercise of this Warrant and on transfers of the
Shares, as the case may be, following exercise of this Warrant, such that any
Shares so acquired shall be held subject to the terms of this Warrant.
14. Governing Law.
This Warrant shall be governed by, and interpreted and
enforced in accordance with, the laws of the State of New York without regard to
principles of choice of law or conflict of laws.
15. Arbitration of Disputes
(a) If any controversy or dispute arises under, out of or in
relation to any of the provisions hereof, such controversy or dispute shall be
submitted for arbitration in New York, New York before a panel of three
arbitrators, one of which shall be selected by the party initiating such
arbitration, one of which shall be selected by the other party and the third of
which (the "Third Arbitrator") shall be selected by the two arbitrators so
selected; provided, however, that in the event that such other arbitrators shall
not agree on the selection of the Third Arbitrator, the Third Arbitrator shall
be selected by the American Arbitration Association located in New York, New
York. Any dispute or controversy submitted to arbitration in accordance with the
provisions of this Section 12.10 shall be determined by such arbitrators in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association then existing.
(b) The arbitrators may award any relief which they shall deem
proper in the circumstances, without regard to the relief which would otherwise
be available to any party in a court of law or equity including, without
limitation, an award of money damages, specific performance, injunctive relief
and/or declaratory relief, however, such an award may not include punitive
damages. The award and findings of the arbitrators shall be conclusive and
binding upon all of the parties hereto, whether or not all parties hereto
participate in the arbitration proceeding, and judgment upon the award may be
entered in any court of competent jurisdiction upon the application of any
party. The parties hereby agree that such courts of competent jurisdiction shall
include, but not be limited to, the courts located in any jurisdiction in which
the party against whom such judgment is being enforced maintains any assets.
-6-
<PAGE>
(c) The prevailing party in the arbitration proceeding shall
be entitled to recover from the other party its reasonable attorneys' fees,
costs and expenses incurred in the proceeding and in any subsequent action to
enforce or collect upon the decision rendered in the arbitration proceeding.
(d) Notwithstanding the foregoing, the parties reserve the
right to seek and obtain injunctive relief, whether in the form of a temporary
restraining order, preliminary injunction, injunction to enforce an arbitration
award, or other order of similar import, from the federal and state courts
located in New York, New York prior to, during, or after commencement or
prosecution or arbitration proceedings of the final decision and award of the
arbitrators; provided, however, that such preliminary injunctive relief shall be
subject to final arbitral decisions.
(e) Each party hereby consents and agrees that the federal and
state courts located in New York, New York each shall have exclusive personal
jurisdiction and proper venue with respect to any such action seeking injunctive
or similar relief hereunder. In any dispute between the parties, neither party
will raise, and each party hereby expressly waives, any objection or defense to
any such court as an inconvenient forum. Each party hereby waives personal
service of any summons, complaint or other process, which may be delivered by
any of the means permitted for notices under Section 11 hereof.
16. Descriptive Headings.
The descriptive headings of the several sections of this
Warrant are inserted for convenience only and shall not control or affect the
meaning or construction of any of the provisions hereof.
WITNESS the seal of the Company and the signature of its duly
authorized officers.
BENTLEY PHARMACEUTICALS, INC.
[SEAL]
By: /s/ James R. Murphy
------------------------------------
James R. Murphy
Chairman and Chief Executive Officer
Attest:
/s/ Michael D. Price
- ---------------------------
Michael D. Price, Secretary
-7-
<PAGE>
SUBSCRIPTION FORM
(To be Executed by the Registered Holder
in order to Exercise the Warrant)
The undersigned hereby irrevocably elects to exercise the
right to purchase _____ Shares by this Warrant according to the conditions
hereof and herewith makes payment of the Purchase Price of such Shares in full.
________________________________
Signature
________________________________
Address
Dated: ___________, _____. ________________________________
Social Security Number or
Taxpayer's Identification Number
-8-
SUBSCRIPTION AGREEMENT
----------------------
BENTLEY PHARMACEUTICALS, INC.
-----------------------------
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
February 11, 1999
Dear Sir or Madam:
Upon the terms and subject to the conditions of an Asset
Purchase Agreement, dated February 1, 1999 effective as of December 31, 1998
(the "Asset Purchase Agreement"), between Conrex Pharmaceutical Corporation
("Conrex ") and Yungtai Hsu ("Hsu"), in which Conrex agreed to sell certain of
its assets to Hsu, Conrex has agreed to accept 359,282 shares (the "Shares") of
common stock, $0.02 par value per share (the "Common Stock") of Bentley
Pharmaceuticals, Inc. (the "Company") as part of the Purchase Price (as defined
in the Asset Purchase Agreement). Therefore, in consideration of the premises
and the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
Conrex hereby agrees to:
1. Subscription. Conrex hereby applies to subscribe for the
Shares. Once this Subscription Agreement (this "Agreement") is executed by both
Conrex and the Company, it is intended to create a binding agreement between
Conrex and the Company with respect to the terms and conditions described below.
2. Representations and Warranties of Conrex. Conrex
acknowledges, represents, warrants and agrees as follows:
(a) Organization and Authorization. Conrex
is a corporation duly organized, validly existing and in good standing under the
laws of the state of New Jersey and is qualified to do business as a foreign
corporation in the State of Pennsylvania and has all requisite corporate power
and authority to purchase and hold the Shares. Conrex has all requisite
corporate power and authority to enter into this Agreement, to purchase the
Shares hereunder and to carry out and perform its obligations under the terms of
this Agreement and the consummation by Conrex of the transactions contemplated
hereby requires no other proceedings on the part of Conrex. The undersigned
signatory has all right, power and authority to execute and deliver this
Agreement on behalf of Conrex. This Agreement has been duly executed and
delivered by Conrex and, assuming the execution and delivery hereof and thereof
by the Company, will constitute the legal, valid and binding obligations of
Conrex, enforceable against Conrex in accordance with its terms, except as the
<PAGE>
same may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting the rights of creditors generally and
the availability of equitable remedies.
(b) Due Diligence. Conrex has received a
copy of such documents as requested by it, has carefully reviewed such
documents, has had the opportunity to obtain any additional information
necessary to verify the accuracy of the information contained in such documents
and has been given the opportunity to meet with representatives of the Company
and to have them answer any questions and provide any additional information
regarding the terms and conditions of this particular investment deemed relevant
by Conrex, and all such questions have been answered and requested information
provided to Conrex's full satisfaction. Among the documents received and
reviewed by Conrex are: (i) the Company's Annual Report on Form 10-K for the
year ended December 31, 1997; (ii) the Company's Quarterly Reports on Form 10-Q
for the quarters ended March 31, 1998, June 30, 1998 and September 30, 1998
(such documents are collectively referred to in this Agreement as the "Exchange
Act Reports"); (iii) the Registration Statement and (iv) a Registration Rights
Agreement between the Company and Conrex with respect to the Shares, dated as of
the date hereof (the "Registration Rights Agreement.") In making its decision to
accept the Shares as part of the Purchase Price, Conrex has relied solely upon
its review of the documents referred to above and this Agreement and independent
investigations made by it or its representatives.
(c) No Legal Advice from the Company. Conrex
acknowledges that it has had the opportunity to review this Agreement and the
transactions contemplated by this Agreement with its own legal counsel and tax
advisors. Except for any statements or representations of the Company made in
this Agreement, in the Exchange Act Reports and in the Registration Rights
Agreement, Conrex is relying solely on such counsel and advisors and not on any
statements or representations of the Company or any of its representative or
agents for legal, tax or investment advice with respect to this investment, the
transactions contemplated by this Agreement or the securities laws of any
jurisdiction.
(d) Not an Affiliate. Conrex is not an
officer, director or "affiliate" (as that term is defined in Rule 405 of the
Act) of the Company.
(e) Reliance on Representations and
Warranties. Conrex understands that the Shares are being offered and sold to it
in reliance on specific provisions of United States federal and state securities
laws and that the Company is relying upon the truth and accuracy of the
representations, warranties, agreements, acknowledgments and understandings of
Conrex set forth in this Agreement in order to determine the applicability of
such provisions.
(f) No Registration. Conrex understands that
the sale of the Shares has not been registered under the Act, in reliance upon
an exemption therefrom by virtue of Section 4(2) and Regulation D promulgated
under the Act. Conrex understands that the Shares must be held indefinitely and
may not be offered, transferred, resold, pledged, hypothecated or otherwise
disposed of until the sale or other transfer thereof is registered under the
Act, pursuant to the terms and conditions of the Registration Rights Agreement
or unless an exemption from such registration
-2-
<PAGE>
is available at that time. Conrex is aware that it will be required to bear the
financial risks of this investment for an indefinite period of time unless
transferred in accordance with the above. Conrex covenants that it will not
knowingly make any sale, transfer or other disposition of the Shares or any
interest therein in violation of the Act, the Exchange Act of 1934, as amended,
or the rules and regulations promulgated under either of said Acts.
(g) Investment Intent. Conrex is acquiring
the Shares solely for its own account as principal and not with a view to the
distribution thereof to or for the benefit or account of any other person, in
whole or in part, and no other person has a direct or indirect beneficial
interest in such Shares. Conrex understands and agrees that it must bear the
economic risk of its investment in the Shares for an indefinite period of time.
Conrex will not take any short position in the Shares and not otherwise engage
in any hedging transactions such as option writing, equity swaps or other types
of derivative transactions with respect to the Shares.
(h) Additional Transfer Restrictions. Conrex
understands and agrees that, in addition to the restrictions set forth in this
Agreement, the following restrictions and limitations are applicable to its
purchase and any resales, pledges, hypothecations or other transfers of the
Shares:
(i) The following legend reflecting all
applicable restrictions will be placed on any certificate(s) or other
document(s) evidencing the Shares and Conrex must comply with the terms and
conditions set forth in such legends prior to any resales, pledges,
hypothecations or other transfers of the Shares:
"THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT") OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES HAVE
BEEN ACQUIRED FOR INVESTMENT PURPOSES
ONLY AND MAY NOT BE OFFERED FOR SALE,
SOLD, HYPOTHECATED, ASSIGNED, PLEDGED OR
OTHERWISE TRANSFERRED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT
COVERING THE SECURITIES UNDER THE ACT OR
APPLICABLE STATE SECURITIES LAWS, OR AN
OPINION OF COUNSEL SATISFACTORY TO THE
ISSUER THAT REGISTRATION IS NOT REQUIRED
UNDER THE ACT OR APPLICABLE STATE
SECURITIES LAWS."
-3-
<PAGE>
(ii) Stop transfer instructions have
been or will be placed on any certificates or other documents evidencing the
Shares so as to restrict the resale, pledge, hypothecation or other transfer
thereof in accordance with the provisions hereof.
(i) Termination of Restrictions. The
restrictions upon the transferability of the Shares shall cease and terminate as
to any particular Shares (i) when, in the opinion of Parker Chapin Flattau &
Klimpl, LLP or other counsel reasonably acceptable to the Company, such
restrictions are no longer required in order to assure compliance with the Act
or (ii) when, in the opinion of Parker Chapin Flattau & Klimpl, LLP or other
counsel reasonably acceptable to the Company, such Shares shall have been
registered under the Act or transferred in reliance upon the exemption afforded
by Section 4(1) of the Act by virtue of Rule 144.
(j) Indemnification. Conrex shall indemnify
and hold harmless the Company and each officer, director or control person of
any such entity, who is or may be a party or is or may be threatened to be made
a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, by reason of or
arising from (i) any actual or alleged misrepresentation or misstatement of
facts or omission to represent or state facts made or alleged to have been made
by Conrex to the Company, (or its agents or representatives), or omitted or
alleged to have been omitted by Conrex, concerning Conrex, or Conrex's authority
to invest or financial position in connection with the offering or sale of the
Shares, or (ii) any breach of warranty or failure to comply with any covenant
contained in this Agreement, including, without limitation, any such
misrepresentation, misstatement or omission, or breach of any warranty or
covenant, contained herein or any other document submitted by Conrex, against
losses, liabilities and expenses for which the Company, or its officers,
directors or control persons has not otherwise been reimbursed (including
attorneys' fees, judgments, fines and amounts paid in settlement in matters
settled in accordance with the provision of the following paragraph) incurred by
the Company, or such officer, director or control person in connection with such
action, suit or proceeding; provided, however, that Conrex will not be liable in
any such case for losses, claims, damages, liabilities or expenses that a court
of competent jurisdiction shall have found in a final judgment to have arisen
primarily from the gross negligence or willful misconduct of the Company or the
party claiming a right to indemnification.
In case any proceeding shall be instituted involving any
person with respect to whom indemnity may be sought, such person (the
"Indemnified Party") shall promptly notify Conrex, and Conrex, upon the request
of the Indemnified Party, shall retain counsel reasonably satisfactory to the
Indemnified Party to represent the Indemnified Party and any others Conrex may
designate in such proceedings and shall pay as incurred the fees and expenses of
such counsel related to such proceeding. In any such proceeding, any Indemnified
Party shall have the right to retain its own counsel at its own expense, except
that Conrex shall pay as incurred the fees and expenses of counsel retained by
the Indemnified Party in the event that (i) Conrex and the Indemnified Party
shall have mutually agreed to the retention of such counsel or, (ii) the named
parties to any such proceeding (including any impleaded parties) include both
Conrex and the Indemnified Party and representation of both parties by the same
counsel would be inappropriate, in the reasonable opinion
-4-
<PAGE>
of the Indemnified Party, due to actual or potential differing interests between
them. Conrex shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a
final judgment for the plaintiff, Conrex agrees to indemnify the Indemnified
Party to the extent set forth in this Agreement.
In the event a claim for indemnification as described herein
is determined to be unenforceable by a final judgment of a court of competent
jurisdiction, then Conrex shall contribute to the aggregate losses, claims,
damages or liabilities to which the Company or its officers, directors, agents,
employees or controlling persons may be subject in such amount as is appropriate
to reflect the relative benefits received by each of the undersigned and the
party seeking contribution on the one hand and the relative faults of Conrex and
the party seeking contribution on the other, as well as any relevant equitable
considerations.
The provisions of this Agreement relating to indemnification
and contribution shall survive termination of this Agreement and shall be
binding upon any successors or assigns of Conrex.
(k) Opportunity to Ask Questions. Conrex has
had a reasonable opportunity to ask questions of and receive answers from the
Company concerning the Company and the transactions contemplated by this
Agreement, and all such questions, if any, have been answered to the full
satisfaction of Conrex.
3. Representations and Warranties of the Company. The Company
acknowledges, represents, warrants and agrees as follows:
(a) Organization and Authorization. The
Company is a corporation duly organized, validly existing and in good standing
under the laws of the state of Florida and has all req uisite corporate power
and authority to own and operate its properties and assets and to carry on its
business as currently conducted. The Company is not in default or violation of
any material term or provision of its Articles of Incorporation or Bylaws nor
will the consummation of the transactions contemplated by this Agreement cause
any such default or violation. The Company has all requisite corporate power and
authority to enter into this Agreement, to sell the Shares hereunder and to
carry out and perform its obligations under the terms of this Agreement subject
to the above. This Agreement is a valid and binding obligation of the Company,
enforceable in accordance with its terms.
(b) Capitalization. The authorized capital
stock of the Company consists of 35,000,000 shares of Common Stock and 2,000,000
shares of Preferred Stock, par value $.02 per share. Upon issuance of the Shares
pursuant to the terms of this Agreement and payment therefor pursuant to the
terms of an Asset Purchase Agreement between Hsu and the Company, the Shares
will be duly authorized, validly issued, fully paid and nonassessable. Upon
issuance, the Shares will not be subject to any preemptive or other preferential
rights or similar statutory or contractual rights.
-5-
<PAGE>
The Closing shall take place as soon as practicable after (i)
due execution by Conrex and acceptance by the Company of this Subscription
Agreement and (ii) the closings as contemplated by the Asset Purchase Agreement
and the Asset Purchase Agreement between Hsu and the Company.
4. Indemnity by the Company. The Company shall indemnify and
hold harmless Conrex and each officer, director or control person of Conrex from
any claims or demands, including without limitation reasonable attorneys fees
and expenses, relating to any liability to ETR and Associates, Robert S. Cohen,
Creative Technologies, Inc., a Delaware corporation with offices in Jersey City,
New Jersey, and/or each of their respective affiliates, for commissions related
to the transactions arising under this Agreement and/or the Asset Purchase
Agreement.
5. Miscellaneous.
(a) Notices. All notices, demands or other
communications to be given or delivered under or by reason of the provisions of
this Agreement shall be in writing and shall be deemed to have been given (a)
when delivered personally to the recipient, (b) when sent to the recipient by
telecopy (receipt electronically confirmed by sender's telecopy machine) if
during normal business hours of the recipient, otherwise on the next Business
Day ("Business Day" means a day other than Saturday, Sunday or any day on which
banks located in the State of New York are authorized or obligated to close),
(c) one Business Day after the date when sent to the recipient by reputable
express courier service (charges prepaid) or (d) seven Business Days after the
date when mailed to the recipient by certified or registered mail, return
receipt requested and postage prepaid. Such notices, demands and other
communications will be sent to Conrex and to the Company at the addresses
indicated below.
If to Conrex, to:
Conrex Pharmaceutical Corporation
5217 West Chester Pike
Newtown Square, Pennsylvania 19073
Attention: Phyllis Hsieh
Facsimile No.: (610) 355-2453
-6-
<PAGE>
with a copy to:
Synnestvedt & Lechner LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Attention: John T. Synnestvedt
Facsimile No.: (215) 923-2189
If to the Company, to:
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
Attention: James R. Murphy
Facsimile: (813) 282-8941
With a copy to:
Parker Chapin Flattau & Klimpl, LLP
1211 Avenue of the Americas
New York, New York 10036
Attention: Mark S. Hirsch
Jordan A. Horvath
Facsimile: (212) 704-6288
(b) Assignment; Benefit. This Agreement may
not be assigned by Conrex without the prior written consent of the Company and
any assignment without such consent shall be void. This Agreement may be
assigned by the Company to any person or entity which purchases all or
substantially all of the stock or assets of the Company or is the successor to
the Company by merger or consolidation. This Agreement shall be binding upon and
inure to the benefit of the respective successors and permitted assigns of the
Company and of Conrex.
(c) Severability. The invalidity or
unenforceability of any provisions of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, each of
which shall remain in full force and effect.
(d) Amendments. This Agreement may be
amended, supplemented or modified, and any provision hereof may be waived, only
pursuant to a written instrument making specific reference to this Agreement
signed by each of the parties hereto.
-7-
<PAGE>
(e) Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument.
(f) Governing Law. This Agreement shall be
governed by and construed in accordance with the laws of the State of New York
applicable to a contract executed and performed in such State without giving
effect to the conflicts of laws principles thereof, except that if it is
necessary in any other jurisdiction to have the law of such other jurisdiction
govern this Agreement in order for this Agreement to be effective in any
respect, then the laws of such other jurisdiction shall govern this Agreement to
such extent.
(g) Arbitration of Disputes
(i) If any controversy or dispute arises
under, out of or in relation to any of the provisions hereof, such controversy
or dispute shall be submitted for arbitration in New York, New York before a
panel of three arbitrators, one of which shall be selected by the party
initiating such arbitration, one of which shall be selected by the other party
and the third of which (the "Third Arbitrator") shall be selected by the two
arbitrators so selected; provided, however, that in the event that such other
arbitrators shall not agree on the selection of the Third Arbitrator, the Third
Arbitrator shall be selected by the American Arbitration Association located in
New York, New York. Any dispute or controversy submitted to arbitration in
accordance with the provisions of this Section shall be determined by such
arbitrators in accordance with the Commercial Arbitration Rules of the American
Arbitration Association then existing.
(ii) The arbitrators may award any
relief which they shall deem proper in the circumstances, without regard to the
relief which would otherwise be available to any party in a court of law or
equity including, without limitation, an award of money damages, specific
performance, injunctive relief and/or declaratory relief, however, such an award
may not include punitive damages. The award and findings of the arbitrators
shall be conclusive and binding upon all of the parties hereto, whether or not
all parties hereto participate in the arbitration proceeding, and judgment upon
the award may be entered in any court of competent jurisdiction upon the
application of any party. The parties hereby agree that such courts of competent
jurisdiction shall include, but not be limited to, the courts located in any
jurisdiction in which the party against whom such judgment is being enforced
maintains any assets.
(iii) The costs of the arbitration and
each party's associated costs shall be borne by the losing party.
Notwithstanding the foregoing, if the parties reach a compromise, the costs of
the arbitration shall be borne equally by the parties and each party shall bear
its own associated costs.
(iv) Notwithstanding the foregoing, the
parties reserve the right to seek and obtain injunctive relief, whether in the
form of a temporary restraining order, preliminary injunction, injunction to
enforce an arbitration award, or other order of similar import,
-8-
<PAGE>
from the federal and state courts located in New York, New York prior to,
during, or after commencement or prosecution or arbitration proceedings of the
final decision and award of the arbitrators; provided, however, that such
preliminary injunctive relief shall be subject to final arbitral decisions.
(v) Each party hereby consents and
agrees that the federal and state courts located in New York, New York each
shall have exclusive personal jurisdiction and proper venue with respect to any
such action seeking injunctive or similar relief hereunder. In any dispute
between the parties, neither party will raise, and each party hereby expressly
waives, any objection or defense to any such court as an inconvenient forum.
Each party hereby waives personal service of any summons, complaint or other
process, which may be delivered by any of the means permitted for notices under
Section 5(a) hereof.
(h) Entire Agreement. This Agreement
constitutes the entire agreement between Conrex and the Company with respect to
the subject matter hereof.
CONREX PHARMACEUTICAL CORPORATION
By: /s/ Phyllis Hsieh
------------------------------
Phyllis Hsieh, President
ACCEPTED AND AGREED:
BENTLEY PHARMACEUTICALS, INC.
By: /s/ James R. Murphy
------------------------------------
James R. Murphy, Chairman, President
and Chief Executive Officer
-9-
REGISTRATION RIGHTS AGREEMENT
-----------------------------
THIS REGISTRATION RIGHTS AGREEMENT, is made and entered into
as of February 11, 1999 between BENTLEY PHARMACEUTICALS, INC., a Florida
corporation (the "Company") and CONREX PHARMACEUTICAL CORPORATION, a New Jersey
corporation ("Conrex").
WHEREAS, upon the terms and subject to the conditions of the
Asset Purchase Agreement, dated February 1, 1999 effective as of December 31,
1998, between Conrex and Yungtai Hsu (the "Asset Purchase Agreement"), in which
Conrex agreed to sell certain of its assets to Mr. Hsu, Conrex has agreed to
accept 359,282 shares (the "Shares") of common stock, $0.02 par value per share
(the "Common Stock") of Bentley Pharmaceuticals, Inc. (the "Company") as part of
the Purchase Price (as defined in the Asset Purchase Agreement);
WHEREAS, to induce Conrex to accept the Shares as part of the
Purchase Price, the Company has agreed to provide certain registration rights
under the Securities Act of 1933, as amended, and the rules and regulations
thereunder, or any similar successor statute (collectively, the "Act"), with
respect to the Shares;
WHEREAS, as of the date hereof, Conrex and the Company entered
into a Subscription Agreement with respect to the Shares (the "Subscription
Agreement");
NOW, THEREFORE, in consideration of the premises and the
mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and Conrex
hereby agree as follows:
1. Definitions.
(a) As used in this Agreement, the following terms shall have
the following meanings:
(i) "Register," "Registered," and "Registration" refer to a
registration effected by preparing and filing a Registration Statement in
compliance with the Act and the declaration or ordering of effectiveness of such
Registration Statement by the United States Securities and Exchange Commission
(the "SEC").
(ii) "Registrable Securities" means the Shares.
(iii) "Registration Statement" means a registration statement
of the Company under the Act, including any amendments or supplements thereto
and prospectuses contained therein.
(iv) "Stockholder" means Conrex and any permitted transferee
or assignee who agrees to become bound by the provisions of this Agreement in
accordance with Section 9 hereof.
<PAGE>
(b) Capitalized terms used herein and not otherwise defined
herein shall have the respective meanings set forth in the Asset Purchase
Agreement.
2. Restrictions on Transfer.
(a) The Stockholder acknowledges and understands that prior to
the registration of the Shares as provided herein, the Shares are "restricted
securities" as defined in Rule 144 promulgated under the Act ("Rule 144"). The
Stockholder understands that the Shares may not be offered, transferred, resold,
pledged, hypothecated or otherwise disposed of in the absence of (i) an opinion
of Parker Chapin Flattau & Klimpl, LLP or other counsel reasonably acceptable to
the Company that such transfer may be made without registration under the Act or
(ii) an opinion of Parker Chapin Flattau & Klimpl, LLP or other counsel
reasonably acceptable to the Company that the Shares have been Registered.
(b) The Stockholder acknowledges that the Company has issued
the Shares to the Stockholder pursuant to an exemption from registration under
the Act. Stockholder represents that (i) it has acquired the Shares for
investment and without any view toward distribution of any of Registrable
Securities to any other person, (ii) it will not sell or otherwise dispose of
the Shares except in compliance with the registration requirements or exemption
provisions under the Act and (iii) before any sale or other disposition of any
of the Shares other than in a sale registered under the Act or pursuant to Rule
144 or 144A (or any similar provisions then in force) under the Act (unless the
Company shall have been advised by counsel that the sale does not meet the
requirements of Rule 144 or Rule 144A, as the case may be, for such sale), it
will deliver to the Company an opinion of counsel, in form and substance
reasonably satisfactory to the Company, to the effect that such registration is
unnecessary.
(c) Each instrument or certificate evidencing or representing
the Shares, and any certificate issued in exchange therefor or transfer thereof,
shall bear legends substantially in the following form:
"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT") OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE
OFFERED FOR SALE, SOLD, HYPOTHECATED, ASSIGNED, PLEDGED OR
OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT COVERING THE SECURITIES UNDER THE ACT
OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED
UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS."
-2-
<PAGE>
3. Registration. The Company shall prepare and file with the
SEC a Registration Statement on April 1, 1999 or as soon as practicable
thereafter on an appropriate form for registering for resale by the Stockholder
the Registrable Securities (or such lesser number as may be required by the
SEC), and the Company shall use its best efforts to cause the Registration
Statement to be declared effective as soon as practicable after filing (the
"Effective Date"). The rights under this paragraph may only be exercised one
time.
4. Obligations of the Company. In connection with a
registration of the Registrable Securities under Section 3 hereof, the Company
shall do each of the following:
(a) Prepare and file with the SEC, a Registration Statement
with respect to the Registrable Securities, and thereafter use its best efforts
to cause each Registration Statement relating to the Registrable Securities to
become effective on the Effective Date, and keep the Registration Statement
effective at all times until the earliest (the "Registration Period") of (i) the
date that is two years after the Closing Date; (ii) the date when the
Stockholder may sell all Registrable Securities under Rule 144 or (iii) the date
the Stockholder no longer owns any of the Registrable Securities, which
Registration Statement shall not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances in which they were
made, not misleading;
(b) Prepare and file with the SEC such amendments (including
post-effective amendments) and supplements to the Registration Statement and the
prospectus used in connection with the Registration Statement as may be
necessary to keep the Registration Statement effective at all times during the
Registration Period, and, during the Registration Period, comply with the
provisions of the Act with respect to the disposition of all Registrable
Securities of the Company covered by the Registration Statement until such time
as all of such Registrable Securities have been disposed of in accordance with
the intended methods of disposition by the seller or sellers thereof as set
forth in the Registration Statement;
(c) The Company shall permit a single firm of counsel
designated by the Stockholder to review the Registration Statement a reasonable
period of time prior to the Company's filing of the Registration Statement with
the SEC;
(d) Furnish to the Stockholder (i) promptly after the
Registration Statement is prepared and publicly distributed, filed with the SEC,
or received by the Company, one copy of the Registration Statement, each
prospectus, and each amendment or supplement thereto, and (ii) such number of
copies of a prospectus, and all amendments and supplements thereto and such
other documents, as the Stockholder may reasonably request in order to
facilitate the disposition of the Registrable Securities owned by the
Stockholder;
(e) As promptly as practicable after becoming aware of such
event, the Company shall notify the Stockholder of (i) the issuance by the SEC
of a stop order suspending the effectiveness of the Registration Statement, (ii)
the happening of any event of which the Company has knowledge as a result of
which the prospectus included in the Registration Statement, as then in
-3-
<PAGE>
effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading, or (iii) the occurrence or existence of any pending corporate
development that, in the reasonable discretion of the Company, makes it
appropriate to suspend the availability of the Registration Statement, and use
its best efforts promptly to prepare a supplement or amendment to the
Registration Statement to correct such untrue statement or omission, and deliver
such number of copies of such supplement or amendment to the Stockholder as it
may reasonably request; provided that, for not more than twenty days (or a total
of not more than forty days in any twelve month period, the Company may delay
the disclosure of material non-public information concerning the Company (as
well as prospectus or Registration Statement updating) the disclosure of which
at the time is not, in the good faith opinion of the Company, in the best
interests of the Company and in the opinion of counsel to the Company (an
"Allowed Delay"); provided, further, that the Company shall promptly (i) notify
the Stockholder in writing of the existence of material non-public information
giving rise to an Allowed Delay and (ii) advise the Stockholder in writing to
cease all sales under the Registration Statement until the end of the Allowed
Delay. Upon expiration of the Allowed Delay, the Company shall again be bound by
the first sentence of this Section 4(e) with respect to the information giving
rise thereto;
(f) As promptly as practicable after becoming aware of such
event, notify the Stockholder who holds Registrable Securities being sold (or,
in the event of an underwritten offering, the managing underwriters) of the
issuance by the SEC of any notice declaring the effectiveness of the
Registration Statement or any stop order or other suspension of the
effectiveness of the Registration Statement at the earliest possible time; and
(g) Take all other reasonable actions necessary to expedite
and facilitate disposition by the Stockholder of the Registrable Securities
pursuant to the Registration Statement.
5. Obligations of the Stockholder. In connection with the
registration of the Registrable Securities, the Stockholder shall have the
following obligations:
(a) It shall be a condition precedent to the obligations of
the Company to complete the registration pursuant to this Agreement with respect
to the Registrable Securities of the Stockholder that the Stockholder shall
furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of the Registrable
Securities held by it, as shall be reasonably required to effect the
registration of such Registrable Securities and shall execute such documents in
connection with such registration as the Company may reasonably request. At
least five days prior to the first anticipated filing date of the Registration
Statement, the Company shall notify the Stockholder of the information the
Company requires from the Stockholder (the "Requested Information") if the
Stockholder elects to have any of the Stockholder's Registrable Securities
included in the Registration Statement. If at least three Business Days (as
defined below) prior to the filing date the Company has not received the
Requested Information from the Stockholder, then the Company may file the
Registration Statement without including Registrable Securities of the
Stockholder;
-4-
<PAGE>
(b) The Stockholder by acceptance of the Registrable
Securities agrees to cooperate with the Company as reasonably requested by the
Company in connection with the preparation and filing of the Registration
Statement hereunder, unless the Stockholder has notified the Company in writing
of the Stockholder's election to exclude all of its Registrable Securities from
the Registration Statement; and
(c) The Stockholder agrees that, upon receipt of any notice
from the Company of the happening of any event of the kind described in Section
4(e) or 4(f), above, the Stockholder will immediately discontinue disposition of
Registrable Securities pursuant to the Registration Statement covering such
Registrable Securities until the Stockholder's receipt of the copies of the
supplemented or amended prospectus contemplated by Section 4(e) or 4(f) and, if
so directed by the Company, the Stockholder shall deliver to the Company (at the
expense of the Company) or destroy (and deliver to the Company a certificate of
destruction) all copies in the Stockholder's possession, of the prospectus
covering such Registrable Securities current at the time of receipt of such
notice.
6. Expenses of Registration.
(a) All reasonable expenses, other than as set forth in
Section 6(b) hereof, filings or qualifications pursuant to Section 4, but
including, without limitation, all registration, listing, and qualifications
fees, printers and accounting fees, the fees and disbursements of counsel for
the Company, shall be borne by the Company.
(b) All underwriting discounts and commissions incurred in
connection with registrations shall be paid by the Stockholder.
7. Indemnification. Conrex shall indemnify and hold harmless
the Company and each officer, director or control person of any such entity, who
is or may be a party or is or may be threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of or arising from (i) any
actual or alleged misrepresentation or misstatement of facts or omission to
represent or state facts made or alleged to have been made by Conrex to the
Company, (or its agents or representatives), or omitted or alleged to have been
omitted by Conrex, concerning Conrex, or Conrex's authority to invest or
financial position in connection with the offering or sale of the Shares in this
Agreement, in the Subscription Agreement or elsewhere, or (ii) any breach of
warranty or failure to comply with any covenant contained in this Agreement or
in the Subscription Agreement, including, without limitation, any such
misrepresentation, misstatement or omission, or breach of any warranty or
covenant, contained herein or any other document submitted by Conrex, against
losses, liabilities and expenses for which the Company, or its officers,
directors or control persons has not otherwise been reimbursed (including
attorneys' fees, judgments, fines and amounts paid in settlement in matters
settled in accordance with the provision of the following paragraph) incurred by
the Company, or such officer, director or control person in connection with such
action, suit or proceeding; provided, however, that Conrex will not be liable in
any such case for losses, claims, damages, liabilities or expenses that a court
of competent jurisdiction shall have found in a final judgment to have arisen
-5-
<PAGE>
primarily from the gross negligence or willful misconduct of the Company or the
party claiming a right to indemnification.
In case any proceeding shall be instituted involving any
person with respect to whom indemnity may be sought, such person (the
"Indemnified Party") shall promptly notify Conrex, and Conrex, upon the request
of the Indemnified Party, shall retain counsel reasonably satisfactory to the
Indemnified Party to represent the Indemnified Party and any others Conrex may
designate in such proceedings and shall pay as incurred the fees and expenses of
such counsel related to such proceeding. In any such proceeding, any Indemnified
Party shall have the right to retain its own counsel at its own expense, except
that Conrex shall pay as incurred the fees and expenses of counsel retained by
the Indemnified Party in the event that (i) Conrex and the Indemnified Party
shall have mutually agreed to the retention of such counsel or, (ii) the named
parties to any such proceeding (including any impleaded parties) include both
Conrex and the Indemnified Party and representation of both parties by the same
counsel would be inappropriate, in the reasonable opinion of the Indemnified
Party, due to actual or potential differing interests between them. Conrex shall
not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for
the plaintiff, Conrex agrees to indemnify the Indemnified Party to the extent
set forth in this Agreement.
In the event a claim for indemnification as described herein
is determined to be unenforceable by a final judgment of a court of competent
jurisdiction, then Conrex shall contribute to the aggregate losses, claims,
damages or liabilities to which the Company or its officers, directors, agents,
employees or controlling persons may be subject in such amount as is appropriate
to reflect the relative benefits received by each of the undersigned and the
party seeking contribution on the one hand and the relative faults of Conrex and
the party seeking contribution on the other, as well as any relevant equitable
considerations.
The provisions of this Agreement relating to indemnification
and contribution shall survive termination of this Agreement and shall be
binding upon any successors or assigns of Conrex.
8. Termination of Registration Rights. The rights granted
pursuant to this Agreement shall terminate as to the Stockholder upon the
occurrence of any of the following:
(a) all of the Registrable Securities have been registered; or
(b) all of the Registrable Securities may be sold without such
registration pursuant to Rule 144.
9. Miscellaneous.
(a) A person or entity is deemed to be a holder of Registrable
Securities whenever such person or entity owns of record such Registrable
Securities. If the Company receives conflicting instructions, notices or
elections from two or more persons or entities with respect to the same
-6-
<PAGE>
Registrable Securities, the Company shall act upon the basis of instructions,
notice or election received from the registered owner of such Registrable
Securities.
(b) Notices. All notices, demands or other communications to
be given or delivered under or by reason of the provisions of this Agreement
shall be in writing and shall be deemed to have been given (a) when delivered
personally to the recipient, (b) when sent to the recipient by telecopy (receipt
electronically confirmed by sender's telecopy machine) if during normal business
hours of the recipient, otherwise on the next Business Day ("Business Day" means
a day other than Saturday, Sunday or any day on which banks located in the State
of New York are authorized or obligated to close), (c) one Business Day after
the date when sent to the recipient by reputable express courier service
(charges prepaid) or (d) seven Business Days after the date when mailed to the
recipient by certified or registered mail, return receipt requested and postage
prepaid. Such notices, demands and other communications will be sent to Conrex
and to the Company at the addresses indicated below.
If to Conrex, to:
Conrex Pharmaceutical Corporation
5127 West Chester Pike
Newtown Square, Pennsylvania 19073
Attention: Phyllis Hsieh
Facsimile No.: (610) 355-2453
with a copy to:
Synnestvedt & Lechner LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Attention: John T. Synnestvedt
Facsimile No.: (215) 923-2189
If to the Company, to:
Bentley Pharmaceuticals, Inc.
Two Urban Centre, Suite 400
4890 West Kennedy Blvd.
Tampa, Florida 33609
Attention: James R. Murphy
Facsimile No.: (813) 282-8941
-7-
<PAGE>
With a copy to:
Parker Chapin Flattau & Klimpl, LLP
1211 Avenue of the Americas
New York, New York 10036
Attention: Mark S. Hirsch
Jordan A. Horvath
Facsimile: (212) 704-6288
(c) Assignment; Benefit. This Agreement may not be assigned by
Conrex without the prior written consent of the Company and any assignment
without such consent shall be void. The rights under this Agreement may be
assigned by Conrex to its Stockholders if Conrex distributes the Shares to its
Stockholders as a dividend to the extent the Shares are distributed to each
Stockholder, provided that such Stockholders agree to be bound by all provisions
of this Agreement and all such transfers are in accordance with all applicable
laws. Upon such assignment Conrex and its Stockholders will have the various
rights under this Agreement which pertain to the Shares then owned by each of
them. This Agreement may be assigned by the Company to any person or entity
which purchases all or substantially all of the stock or assets of the Company
or is the successor to the Company by merger or consolidation. This Agreement
shall be binding upon and inure to the benefit of the respective successors and
permitted assigns of the Company and of Conrex.
(d) Severability. The invalidity or unenforceability of any
provisions of this Agreement shall not affect the validity or enforceability of
any other provision of this Agreement, each of which shall remain in full force
and effect.
(e) Amendments. This Agreement may be amended, supplemented or
modified, and any provision hereof may be waived, only pursuant to a written
instrument making specific reference to this Agreement signed by each of the
parties hereto.
(f) Counterparts. This Agreement may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
(g) Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to a
contract executed and performed in such State without giving effect to the
conflicts of laws principles thereof, except that if it is necessary in any
other jurisdiction to have the law of such other jurisdiction govern this
Agreement in order for this Agreement to be effective in any respect, then the
laws of such other jurisdiction shall govern this Agreement to such extent.
-8-
<PAGE>
(h) Arbitration of Disputes
(i) If any controversy or dispute arises
under, out of or in relation to any of the provisions hereof, such controversy
or dispute shall be submitted for arbitration in New York, New York before a
panel of three arbitrators, one of which shall be selected by the party
initiating such arbitration, one of which shall be selected by the other party
and the third of which (the "Third Arbitrator") shall be selected by the two
arbitrators so selected; provided, however, that in the event that such other
arbitrators shall not agree on the selection of the Third Arbitrator, the Third
Arbitrator shall be selected by the American Arbitration Association located in
New York, New York. Any dispute or controversy submitted to arbitration in
accordance with the provisions of this Section shall be determined by such
arbitrators in accordance with the Commercial Arbitration Rules of the American
Arbitration Association then existing.
(ii) The arbitrators may award any relief
which they shall deem proper in the circumstances, without regard to the relief
which would otherwise be available to any party in a court of law or equity
including, without limitation, an award of money damages, specific performance,
injunctive relief and/or declaratory relief, however, such an award may not
include punitive damages. The award and findings of the arbitrators shall be
conclusive and binding upon all of the parties hereto, whether or not all
parties hereto participate in the arbitration proceeding, and judgment upon the
award may be entered in any court of competent jurisdiction upon the application
of any party. The parties hereby agree that such courts of competent
jurisdiction shall include, but not be limited to, the courts located in any
jurisdiction in which the party against whom such judgment is being enforced
maintains any assets.
(iii) The costs of the arbitration and each
party's associated costs shall be borne by the losing party. Notwithstanding the
foregoing, if the parties reach a compromise, the costs of the arbitration shall
be borne equally by the parties and each party shall bear its own associated
costs.
(iv) Notwithstanding the foregoing, the
parties reserve the right to seek and obtain injunctive relief, whether in the
form of a temporary restraining order, preliminary injunction, injunction to
enforce an arbitration award, or other order of similar import, from the federal
and state courts located in New York, New York prior to, during, or after
commencement or prosecution or arbitration proceedings of the final decision and
award of the arbitrators; provided, however, that such preliminary injunctive
relief shall be subject to final arbitral decisions.
(v) Each party hereby consents and agrees
that the federal and state courts located in New York, New York each shall have
exclusive personal jurisdiction and proper venue with respect to any such action
seeking injunctive or similar relief hereunder. In any dispute between the
parties, neither party will raise, and each party hereby expressly waives, any
objection or defense to any such court as an inconvenient forum. Each party
hereby waives personal service of any summons, complaint or other process, which
may be delivered by any of the means permitted for notices under Section 10(b)
hereof
-9-
<PAGE>
IN WITNESS WHEREOF, the parties have executed and delivered
this Agreement as of the day and year first written above.
BENTLEY PHARMACEUTICALS, INC.
By: /s/ James R. Murphy
-----------------------------------
James R. Murphy, Chairman, President
and Chief Executive Officer
CONREX PHARMACEUTICAL CORPORATION
By: /s/ Phyllis Hsieh
----------------------------------
Phyllis Hsieh, President
-10-
